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As lifespan is increasing globally, there is a critical need to identify strategies to extend
healthspan and prevent chronic diseases into older age. The long-term goal of my
research is to identify novel strategies to ameliorate aging-induced decline in
hematopoietic stem cell (HSC) function. HSCs give rise to all mature blood and immune
cells. With age, HSCs undergo defects in their differentiation ability which correlates
with a decline in immune function. Lack of comprehensive knowledge of gene regulatory
and epigenetic mechanisms underlying this defect is a barrier to developing therapies to
ameliorate aging-associated decline in HSC function. Therefore, my project focuses on
understanding the gene regulatory mechanisms underlying this decline in HSC function.
Before delving into the gene regulatory mechanisms that go awry with age, it is important
to identify which mechanisms are important for the differentiation of HSCs to mature
cells. The majority of screening approaches for the identification of novel genes and gene
iii

regulatory elements rely on robust in vitro assays. I have demonstrated that one such
assay widely used in the field to differentiate hematopoietic stem and progenitor cells
(HSPCs) to B-lymphoid cells performs in a qualitative rather than a quantitative manner
which calls into question interpretations of results of this assay. Also, by mining publicly
available gene expression data sets and data from an unpublished shRNA knockdown
screen, I have identified that the epigenetic regulator lysine acetyltransferase 6b (Kat6b)
is important for HSC function as well as demonstrated that KAT6B levels are
significantly decreased in expression in aged long term-hematopoietic stem cells (LTHSCs) at the transcript and protein levels using qPCR and immunofluorescence. In
addition, I have observed that knockdown of Kat6b leads to enhanced myeloid
differentiation from LT-HSCs by using in vitro and in vivo assays which partially
replicates aging-associated hematopoietic phenotypes. Transcriptome analysis suggests
that Kat6b knockdown in LT-HSCs leads to dysregulation of differentiation signatures
and an increase in inflammation. These data support increasing the levels of Kat6b as a
novel therapeutic strategy for ameliorating aging-associated hematopoietic decline.
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CHAPTER 1
INTRODUCTION
1.1. The hematopoietic system generates blood and immune cells
Blood development (hematopoiesis) is the process of generating and replenishing
blood and immune cells throughout the lifespan of an organism (Orkin, 2000). The
cellular products of the hematopoietic system can be broadly classified into three main
lineage types: erythroid, myeloid and lymphoid lineages (Figure 1.1).

Figure 1.1. The hematopoietic system generates immune and blood cells.

The lymphoid lineage consists of B, T and natural killer (NK) cells. B and T cells
constitute the adaptive part of the immune system whereas NK cells contribute to the
innate immune system (Olsen Saraiva Camara, Lepique, & Basso, 2012). These
lymphocytes execute their functions in several ways including direct interrogation of
foreign pathogens and activation of components of the innate immune system like
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macrophages (Olsen Saraiva Camara et al., 2012). The myeloid compartment consists of
dendritic cells, monocytes, macrophages and, granulocytes (Bassler, Schulte-Schrepping,
Warnat-Herresthal, Aschenbrenner, & Schultze, 2019). These cells contribute to the
immune system by phagocytosis of foreign particles and by secreting inflammatory
cytokines (Kawamoto & Minato, 2004). The erythroid lineage broadly incorporates
megakaryocytic and erythroid lineages which are responsible for the production of
platelets and red blood cells respectively. A rare population of cells in the bone marrow,
HSCs, is responsible for generating all these cells through by tightly regulated processes
of differentiation and self-renewal (Orkin, 2000) where self-renewal consists of stem
cells dividing to produce more stem cells (He, Nakada, & Morrison, 2009).
1.1.1. Historical identification of HSCs
Roots of stem cells can be traced to Ernst Haeckel, a German Biologist, who first
employed the term “Stammzelle” (stem cell) to represent a unicellular organism from
which all other organisms evolved (Ramalho-Santos & Willenbring, 2007). He later
proposed that a fertilized egg can be also described as a stem cell (Ramalho-Santos &
Willenbring, 2007). Later, Boveri proposed that cells that lie on the developmental
trajectory between a fertilized egg and committed germ cells should be called stem cells.
These ideas represented the first characteristic of a stem cell, that is, the ability to give
rise to multiple cell lineages. Later, Häcker observed that a particular cell in Cyclops,
which he also called a stem cell, went through asymmetric differentiation and gave rise to
mesoderm and a germ cell (Ramalho-Santos & Willenbring, 2007). This provided the
second key characteristic of stem cells, that is, the ability to self-renew. Although, we
now know that “stem cells” mentioned in these early studies represented germline stem
2

cells (Ramalho-Santos & Willenbring, 2007), these studies were critical in establishing
the key characteristics of stem cells. Roughly at the same time the aforementioned ideas
were being investigated, the identification of different types of white blood cells by Paul
Ehlrich had sparked a debate about the existence of a single precursor of the
hematopoietic system (Ramalho-Santos & Willenbring, 2007). One school of thought
held the theory that myeloid and lymphoid cells originated from distinct progenitors and
took place in distinct anatomical locations, whereas the other school of thought held the
opinion that myeloid, erythroid and lymphoid cells originate from a single precursor
(Ramalho-Santos & Willenbring, 2007).
This issue was resolved when key studies done in the 1960s by Till and
colleagues and others showed the presence of a single hematopoietic progenitor cell
which could give rise to myeloid, erythroid and lymphoid cells and had the ability to selfrenew. Transplantation of nucleated bone marrow cells in irradiated recipients produced
colony forming units (CFUs) in recipients’ spleens (Till & McCulloch, 2012). These
CFUs consisted of erythroblast, myelocytes, metamyelocytes as well as megakaryocytes
(Till & McCulloch, 2012). Similar experiments also provided evidence that these CFUs
in the spleen (CFU-S) could also give rise to the lymphoid cells in the thymus (Wu, Till,
Siminovitch, & McCulloch, 1968). These were the first reports which provided evidence
for the existence of cells in the bone marrow having the ability to differentiate into the
three hematopoietic lineages, which is one of the key characteristics of HSCs. When
CFU-S were harvested from spleens of recipient mice and transplanted into secondary
recipients, spleens of these recipients also harbored CFU-S (Siminovitch, McCulloch, &
Till, 1963), which further showed that progenitor cells exist in the bone marrow that have
3

multilineage differentiation as well as self-renewal abilities. However, these studies still
did not provide proof that a single progenitor cell in the bone marrow had the ability to
give rise to a complete CFU-S. This proof was provided when donor bone marrow cells
were irradiated before transplantation into recipients (Becker, McCulloch, & Till, 1963).
Irradiation of these donor bone marrow cells resulted in each cell having a distinct
karyotype. The cells within a single CFU-S colony in recipients were observed to contain
similar karyotypes (Becker et al., 1963). This study showed that CFU-S arises from a
single progenitor cell in the bone marrow of donor mice which had multilineage
differentiation and self-renewal ability. Therefore, these studies provided the evidence, in
the context of spleen colony units, for the existence of a stem cell that satisfied the key
characteristics of HSC. However, the identity of HSCs was not revealed until cells were
prospectively isolated by distinct cell surface markers (Weissman & Shizuru, 2008),
starting from the enrichment of HSCs based on the Sca1+ cell surface maker (Spangrude,
Heimfeld, & Weissman, 1988). This ability to isolate HSCs allowed elucidation of the
journey of HSCs during development and adult stages.
1.1.2. Developmental hematopoiesis
Hematopoiesis in vertebrates occurs in two waves; the primitive wave and the
definitive wave (Galloway & Zon, 2003). The primitive wave generates unipotent
progenitors like nucleated erythrocytes whereas the definitive wave involves the
production of multipotent progenitors like HSCs (Dzierzak & Bigas, 2018; Galloway &
Zon, 2003). The definitive wave can sustain hematopoiesis for the lifespan of an
organism. These two waves of hematopoiesis take place in distinct anatomical locations
(Galloway & Zon, 2003) which will be described in the following sections.
4

1.1.2.1. Primitive hematopoiesis
The hematopoietic system in mice arises in the mesodermal germ layer (Dzierzak
& Medvinsky, 1995). This primitive hematopoiesis primarily produces cells of erythroid,
megakaryocytic and myeloid lineages (Palis, 2016) with limited lymphoid potential, and
originates from the yolk sac blood islands which are considered to be the first site for
development of blood and vascular systems in vertebrate embryos (Ferkowicz & Yoder,
2005). In mice, blood islands, also known as mesodermal cells masses or angioblastic
cords, originate from mesodermal cells in the yolk sac between E7-E7.5 (Palis & Yoder,
2001). Visceral endoderm in the yolk sac provides the signals which lead to formation of
blood cells (Palis & Yoder, 2001). Extra-embryonic mesodermal sheet gives rise to
mesodermal masses which serve as precursors for blood islands which contain common
endothelial and hematopoietic progenitors called hemangioblasts.(Ferkowicz & Yoder,
2005). Hemangioblasts give rise to a common erythroid and megakaryocyte progenitor
(Tober et al., 2007).
The cells on the outer layer of the blood island differentiate into endothelial cells
whereas inner cells differentiate into primitive erythroblasts (Palis & Yoder, 2001). These
erythroblasts start circulation in the embryo proper when cardiac contractions start at
E8.25 (Palis, 2016). These primitive erythroblasts go through several changes involving
reduction in cell size, production of hemoglobin, mitochondria loss, nuclear condensation
and, express embryonic globin genes (Palis, 2016). Primitive erythroblasts become
enucleated around E12.5-E16.5 and are found to be in circulation a few days after birth
(Palis, 2016).
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Megakaryocyte progenitors also start to appear around E7.5-E10.5 with limited
potential for endoreduplication (Tober et al., 2007), which is the process of replication of
the genome without cell division (Ullah, Lee, Lilly, & DePamphilis, 2009). A limited
number of platelets are also found to be circulating starting from E9.5 (Palis, 2016).
Similar to primitive megakaryocyte cells, primitive myeloid cells originate at
E7.25 having predominantly macrophage differentiation potential (Palis, 2016).
However, myeloid progenitors with neutrophil, mast cell, and granulocyte-macrophage
differentiation potential start to appear from E8.25 (Palis, 2016). In addition, E8 - E9 yolk
sac was found to have B and T-cell reconstitution potential in recipient mice which were
deficient for B and T-cells (Palacios & Imhof, 1993). Tracking of labeled yolk sac cells
in recipient mice also revealed that these cells gave rise to adult HSCs (Samokhvalov,
Samokhvalova, & Nishikawa, 2007). Therefore, these studies showed that after E8-9
hematopoietic progenitor cells in the yolk can be defined as stem cells because of their
multilineage differential and self-renewal potential.
1.1.2.2. Definitive hematopoiesis
The aorta, gonad, mesonephros (AGM) region is the primary site for definitive
hematopoiesis (Zon, 1995). Cells from the AGM were observed to have 200 times more
CFU-S as compared to yolk sac on day 10 days post coitum (DPC) in mice (Medvinsky,
Samoyllna, Miillert, & Dzlerzakt, 1993; Sánchez, Holmes, Miles, & Dzierzak, 1996)
which shows that cells from the AGM contain cells with characteristics similar to the
HSCs. CFU-S content starts to decline in the AGM from DPC 11 which coincides with
an increase in CFU-S in the fetal liver (Medvinsky et al., 1993). In addition, cells from
the aorta were found to migrate into the lumen of the aorta which showed the exit of
6

potential HSCs towards fetal liver (Galloway & Zon, 2003). This results in the fetal liver
becoming the next site for the hematopoietic development.
The fetal liver provides the next niche for definitive hematopoiesis where
hematopoietic progenitors undergo expansion and maturation (Ciriza, Thompson,
Petrosian, Manilay, & García-Ojeda, 2013). At around 12.5 DPC HSCs go through
expansion and differentiation mainly in the fetal liver (Mikkola & Orkin, 2006). Initially,
fetal liver hematopoiesis focuses on the production of erythroid cells, which later
incorporates the production of myeloid and lymphoid cells as well (Mikkola & Orkin,
2006).
As mentioned before, nucleated erythroblasts decline and nonnucleated erythroid
cells increase in circulation by 12 DPC (Galloway & Zon, 2003). HSCs start to populate
long bones from E17.5 (Mikkola & Orkin, 2006).
Fetal liver HSCs contain several differences as compared to adult HSCs (Beaudin
et al., 2016; Bowie et al., 2007; Matsuoka et al., 2001). Transplantation of CD34- and
CD34+ HSCs from fetal liver and adult bone marrow in irradiated mice showed that fetal
HSCs are marked with CD34+ whereas adult HSCs (after 8 weeks of age) are marked by
CD34- (Matsuoka et al., 2001). Besides, fetal HSCs have a higher capacity for
regeneration of HSCs as compared to their 4-week old counterparts (Bowie et al., 2007).
This is accompanied by higher expression of genes associated with HSC cycling/selfrenewal (e.g. IKAROS family zinc finger 1 (Ikaros), Polyhomeotic 1 (Rae-28)) in fetal
HSCs as compared to adult HSCs (Bowie et al., 2007). Fetal HSCs also produced a
higher percentage of myeloid cells when transplanted into irradiated recipients (Bowie et
al., 2007). These observations show that fetal HSCs perform the function of generating a
7

higher number of HSCs which can sustain hematopoiesis for the lifespan for an organism.
However, in adulthood, the focus of the hematopoietic system switches to the
maintenance of numbers of HSCs.
1.1.3. Bone marrow hematopoiesis
Adult HSCs are responsible for production of all mature blood and immune cells.
However, the differentiation pathways that lead to mature cells from HSCs have been
revised several times (Y. Zhang, Gao, Xia, & Liu, 2018). In the 2000s, HSCs were
considered to undergo sequential differentiation steps producing progenitors with
successive restriction in self-renewal and differentiation potential ultimately leading to
the generation of mature cells (Adolfsson et al., 2005; Akashi K, Traver D, Miyamoto T,
& IL, 2000; Kondo, Weissman, & Akashi, 1997; Morrison, Wandycz, Hemmati, Wright,
& Weissman, 1997; L. Yang et al., 2005).

8

Figure 1.2. The classical hierarchy of the hematopoietic system.
According to this classical view of the hematopoietic hierarchy (Figure 1.2), LTHSCs have long term reconstitution ability which was assessed by multilineage
chimerism of donor LT-HSCs for 15 weeks after being transplanted into the primary
recipient mice (Christensen & Weissman, 2001; Mastake, Hanada, Hamada, & Nakauchi,
1996) as well as self-renewal ability which was assessed by chimerism in the secondary
recipients (Smith, Weissman, & Heimfeldtt, 1991). These LT-HSCs then differentiate
into short-term HSCs (ST-HSCs) which still retain multilineage differentiation ability but
do not have long term (greater than 15-16 weeks) reconstitution ability like LT-HSCs (L.
Yang et al., 2005). ST-HSCs have faster kinetics of reconstituting recipients as compared
to LT-HSCs (L. Yang et al., 2005), suggesting that ST-HSCs might contribute more
towards steady-state hematopoiesis as compared to LT-HSCs. ST-HSCs give rise to
9

multipotent progenitors (MPPs) which have multi-lineage reconstitution ability with no
self-renewal potential (Y. Zhang et al., 2018). After MPPs, myeloid and lymphoid
lineages separate into lineage-committed progenitors; common lymphoid progenitors
(CLPs) and common myeloid progenitors (CMPs) respectively (Akashi K et al., 2000;
Kondo et al., 1997). CLPs, identified by the expression of the interleukin 7 receptor
(IL7RA) marker, were found to harbor B and T-cell reconstitution ability with no
myeloid reconstitution ability in vivo (Kondo et al., 1997) and expressed low levels of
genes like GATA binding protein 3 (Gata-3) and paired box 5 (Pax5) which are
important for the lymphoid lineage (Akashi K et al., 2000). Whereas, CMPs, identified by
the absence of IL7RA marker, were found to have in vitro and in vivo myeloid and
erythroid differentiation ability (Akashi K et al., 2000) but had no B and T-cell
reconstitution ability (Boyer et al., 2019). CMPs gave rise to granulocyte-macrophage
progenitors (GMPs) and megakaryocyte erythrocyte progenitors (MEPs). Transplantation
of MEPs in irradiated recipients only produced TER119+ erythroid cells, whereas GMPs
only produced MAC1+/GR1+ myeloid cells in similar experiments (Akashi K et al.,
2000). GMPs and MEPs were found to express genes important for myeloid and
erythroid lineages respectively (Akashi K et al., 2000). Therefore, according to these
earlier studies HSCs went through stepwise restriction of lineage fates starting from
separation of the lymphoid lineage from the myeloid/erythroid lineages, followed by the
separation of the erythroid lineage from the myeloid lineage.

10

Figure 1.3. The revised hierarchy of the hematopoietic system.
The aforementioned classical view of the hematopoietic hierarchy began to be
revised (Figure 1.3) with the identification and characterization of different types of
MPPs (Cabezas-Wallscheid et al., 2014; Pietras et al., 2015b; Wilson et al., 2008). New
MPPs (MPP1, MPP2, MPP3, and MPP4) were identified by varied expression patterns of
CD150, CD48, and CD135 cell surface markers (Wilson et al., 2008). HSPCs were
defined by following cell surface markers: LT-HSCs (lineage- Sca1+ cKit+ Flt3- CD150+
CD48-), ST-HSCs (lineage- Sca1+ cKit+ Flt3- CD150- CD48-), MPP2 (lineage- Sca1+
cKit+ Flt3- CD150+ CD48+), MPP3 (lineage- Sca1+ cKit+ve Flt3- CD150- CD48+) and
MPP4s (lineage- Sca1+ cKit+ Flt3+ CD150-) (Pietras et al., 2015a).
These MPPs also showed different quiescence and cell cycling properties, with
MPP1s being the most quiescent and MPP2, MPP3, and MPP4s showing higher cycling
(Wilson et al., 2008). Using a combination of in vitro CFU and in vivo reconstitution
11

experiments, MPP2s were found to be biased towards the megakaryocyte/erythroid
lineage, MPP3s were biased towards myeloid lineages whereas MPP4s had a lymphoid
bias (Pietras et al., 2015a). However, all of these MPPs were found to have minor
contributions towards the rest of the two lineages which they were not biased towards:
MPP2s had myeloid and lymphoid contributions, MPP3s had lymphoid and erythroid
contributions, and MPP4s had myeloid and erythroid differentiation potential (Pietras et
al., 2015a). These studies provided evidence against strict restriction of lineage potential
during differentiation of HSCs to mature cells which had been presented by earlier
studies.

Figure 1.4. Hematopoiesis is a process of continuous differentiation.
The advent of single-cell genome technologies enabled a more thorough
interrogation of the differentiation potential of hematopoietic cells (Y. Zhang et al.,
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2018). Single-cell RNA-seq (scRNA-seq) of HSPCs has now shown that the
differentiation potential of these cells changes along a continuum rather than discrete
states in mice (Dahlin et al., 2018). These findings were also observed in human
hematopoiesis, where investigation of single-cell chromatin accessibility (scATAC-seq)
revealed a continuous relationship among hematopoietic cells and also showed
heterogeneity among cell populations which were considered to be homogenous by
characteristic cell surface maker patterns (Buenrostro et al., 2018). These studies support
a model of hematopoiesis in which HSPCs lie on a continuous spectrum of differentiation
potential rather than following discrete steps which then ultimately produces mature cells
(Figure 1.4).
1.1.4. Assays for assessing differentiation of HSPCs
Studies involving hematopoiesis have relied on a variety of in vitro and in vivo
assays for assessing the functional potential of HSPCs.
1.1.4.1. In vitro assays
In vitro assays for interrogating the differentiation potential of HSPCs can be
broadly classified into liquid culture assays and semi-solid methylcellulose-based assays.
Liquid culture-based assays involve culturing of HSPCs in presence of growth factors
which promote differentiation to towards each lineage or combination of
erythroid/myeloid and lymphoid lineages which is followed by an assessment of the
differentiation potential by flow cytometry (Adolfsson et al., 2005; Young et al., 2016a).
For assessment of B-lymphoid differentiation potential, co-culture with OP-9 stromal
cells has been employed (Nakano, Kodama, & Honjo, 1994; Pietras et al., 2015a; Viera
& Cumano, 2004). Colony forming unit (CFU) assays provide a measure of number and
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type of progenitor cells by using defined methylcellulose media (Purton & Scadden,
2007). Specific methylcellulose media are commercially available which promote
differentiation to myeloid, erythroid or lymphoid lineages. These CFU assays produce
colonies whose number and morphology give a measure of the respective type of
progenitor present in the population of cells that was plated in the assay.
1.1.4.2. In vivo assays
In vivo assays for assessment of hematopoietic stem/progenitor cells involve
transplantation of the respective population into myeloablated recipients (Adolfsson et
al., 2005; Pietras et al., 2015a). The ability of transplanted cells to reconstitute the
recipient hematopoietic system is measured by the peripheral blood composition of the
recipient mice by flow cytometry. For assessment of long-term reconstitution potential
transplanted mice are observed for 4-6 months (Purton & Scadden, 2007). For
determination of true hematopoietic stem cell function involving self-renewal, bone
marrow from primary recipients is transplanted into secondary myeloablated recipients to
assess multilineage reconstitution potential. The ability to reconstitute secondary
recipients shows self-renewal potential of the transplanted population.
1.2. Changes in the hematopoietic system with age
1.2.1 Functional changes in the immune system with age
Aging involves a progressive decline in a variety of cellular systems which results
in a decline in the healthspan, the period of time from birth until the organism remains
free from chronic diseases and aging-associated diseases (Kaeberlein, 2018). Among
these changes, reduction in immune system function has a significant contribution to the
shortening of healthspan. As the immune system is responsible for detection and
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neutralizing pathogens and foreign particles (Parkin & Cohen, 2001), the elderly become
more susceptible to infections leading to more frequent and severe infections (Dorshkind,
& Swain, 2009). For example, 80-90% of the mortalities due to infection by influenza
occur in individuals 65 years or older (Dorshkind, Montecio-Rodriguez, & Signer, 2009).
Aging also involves deterioration in the efficiency of vaccination and the diminished
ability of immune cells to detect malignant cells (Ponnappan & Ponnappan, 2011). In the
context of human bone marrow transplantation, marrow from older individuals is less
successful at reconstituting the immune system in recipients (Dorshkind et al., 2009).
Another functional consequence of aging is an increase in the incidence of anemia, which
is linked to dementia and cardiovascular disease (Ferrucci & Balducci, 2003).
1.2.2. Changes in the adaptive immune system with age
Functional degeneration of the immune system is associated with changes in both
the adaptive and innate systems. The adaptive immune system consists of antigenspecific responses to pathogens mounted by T and B lymphocytes, whereas the innate
immune system involves chemical, physical and microbiological barriers and cellular
responses by monocytes, neutrophils, macrophages, complement, cytokines and acute
phase proteins (Parkin & Cohen, 2001). Age-associated regression in adaptive immunity
involves changes in both T cell and B cells. With age, T cell proliferation decreases in
vitro and in vivo and number of naive T cells decrease with a corresponding increase in
memory T cells (Miller, 1996). Contrary to T cells, overall numbers of B cells in
peripheral lymphoid organs do not change with age (Kogut, Scholz, Cancro, & Cambier,
2012). However, there is an increase in the proportion of B cells derived from a relatively
small number of clones (Miller, 1996). Germinal centers are a collection of B-cells that
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are responsible for the generation of diverse and specific antibodies which also involves
somatic hypermutation (Victora & Nussenzweig, 2012). Antibody diversity (generated by
hypermutation in germinal centers) also diminishes with age and overall antibody
production declines as well (Miller, 1996).
1.2.3. Changes in the innate immune system with age
Activation of the innate immune system with age results in misregulation of
inflammatory responses (Shaw, Goldstein, & Montgomery, 2013). This involves
upregulation of pro-inflammatory cytokines like interleukin-6 (IL-6), interleukin-18 (IL18), interleukin-1β (IL-1β) and tumor necrosis factor (TNFα) (Mcmichael, Simon, &
Hollander, 2015). Neutrophils and macrophages are effectors of the innate immune
system (Solana, Pawelec, & Tarazona, 2006). Neutrophils are the first to arrive at sites
infected by pathogens, and their ability to migrate in and out of infectious sites decreases
with age (Shaw et al., 2013). Aging is also associated with a decline in the phagocytotic
ability of both neutrophils and macrophages as well as decreased cytotoxic activity
towards phagocytosed pathogens (Shaw et al., 2013).
1.2.4. Changes in HSCs with age:
Intuitively, the frequency of HSCs should decrease with age, which would
correspond with a decline in the immune function. However, quantification of HSCs with
different types of HSC specific staining schemes shows that the frequency of HSCs
actually increases with age in mice (Dykstra, Olthof, Schreuder, Ritsema, & De Haan,
2011; Morrison, Andycz1, & Weissman, 1996; Rodrigues, Maciel-Filho, Asenjo, Zaror,
& Maugeri, 1997; Sudo, Ema, Morita, & Nakauchi, 2000) and humans (Taraldsrud et al.,
2009). Increased variability in the frequency of HSCs among old mice was also observed
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(Dykstra et al., 2011). However, increased HSCs’ frequency is not followed by a
corresponding increase in the function of HSCs. Approximately ten HSCs from 2-14month old mice were able to achieve 63% limiting dilution frequency (the frequency of
transplanted cells at which 63% of transplanted recipients showed reconstitution of
hematopoietic system) of irradiated recipients when co-injected with 2 x 105 support
cells, whereas 40 HSCs from 24-month-old mice were required to achieve the same
results (Morrison et al., 1996). Reduction in the ability of individual HSC to form
colonies was also shown by decreased cobblestone area forming capacity, which
measured the in vitro differentiation ability of stem cells (Theilgaard-Mönch, 2008), of
old HSCs (Dykstra et al., 2011). This shows that the overall reconstitution ability of
HSCs decreases with age. In addition to increases in numbers of HSCs, the lineage
capacity of HSCs also changes with age. HSCs from old mice are biased towards the
myeloid lineage at the expense of the lymphoid lineage (Chung & Park, 2017).
Transplantation of old HSCs compared to young HSCs leads to higher myeloid
reconstitution and lower lymphoid reconstitution capacity which included increased
percentages of GMPs and decreased percentages of CLPs (Rodrigues et al., 1997).
Therefore, aged HSCs have higher myeloid and lower lymphoid differentiation potential
(Figure 1.5).
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Figure 1.5. Cellular changes in HSC lineage potential with age.
However, these studies involved transplantations that are conducted under nonphysiological conditions involving isolation of cells from their normal environment
inside the bone marrow and exposure various kind of stresses in the process. The results
of those experiments might not provide an accurate picture of HSC function in
endogenous conditions (Säwen et al., 2018). Native labeling, which involves labelling of
the cells in endogenous niches like bone marrow, of old and young HSCs has shown that
multilineage differentiation ability decreases with age (Säwen et al., 2018). The
frequency of platelet-biased HSCs increases with age as well, along with enrichment for
gene signatures corresponding to pre-MegE (megakryocyte/erythroid) and
megakaryocyte genes (Grover et al., 2016). Apart from impaired regenerative and
differentiation abilities, HSCs from old mice also have reduced homing capability
(Dykstra et al., 2011).
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Therefore, HSCs undergo several changes during aging, consisting of an increase in
frequency, a bias towards differentiation to the myeloid cell types, and a decrease
towards differentiation to the lymphoid cell types. That is why it is important to identify
gene regulatory and epigenetic mechanisms driving these changes in HSCs with age.
1.3. Epigenetics and hematopoiesis
1.3.1. Introduction to epigenetics
The development of complex multicellular organisms from single cells involves a
series of differentiation and division cycles while maintaining the same genome
sequence. Changes in gene expression profiles are critical processes for the regulation of
cell fate which aids in the development of a complex organism. Additionally,
homeostasis and preservation of cellular identity through cellular division requires
specific gene expression patterns to be maintained. Epigenetic mechanisms orchestrate
these changes in gene expression profiles via changes in chromatin accessibility. The
term ‘epigenetics’ was coined by Conrad Waddington and was defined as “the branch of
biology which studies the causal interactions between genes and their products, which
bring the phenotype into being” (Goldberg, Allis, & Bernstein, 2007). This involves
heritable variation that occurs without changes in the DNA sequence (Butler & Dent,
2013a). DNA is wrapped around histones that are made up of a tetramer of histone
proteins H2A, H2B, H3 and H4 which constitute a nucleosome (T. Chen & R Dent,
2013). N- and C- terminal tails of these histone proteins are exposed and have the ability
to interact with surrounding nucleosomes and linker DNA that connects adjacent
nucleosomes (T. Zhang, Cooper, & Brockdorff, 2015). Covalent modifications of DNA
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and histone tails can lead to direct reversible changes in chromatin structure and also
serve as binding sites for recruitment of other non-histone proteins like adenosine
triphosphate (ATP) dependent chromatin remodeling complexes, which exchange
different types of histone and change position of histones by using energy from ATP
hydrolysis (T. Chen & R Dent, 2013). Packaging and accessibility status of chromatin on
target loci dictate their pattern of expression. Tightly packaged chromatin is considered
heterochromatin and is associated with transcriptional repression, whereas accessible
chromatin is considered euchromatin and is associated with transcriptional activation (T.
Chen & R Dent, 2013). Epigenetic processes that lead to changes in chromatin
architecture involve DNA methylation and post-translational modifications of the histone
tails (Butler & Dent, 2013a). Replacement of canonical histones by non-canonical
histones like H3.3 and H2A.Z can also serve to modify the chromatin accessibility and
modify the expression of target loci (T. Zhang et al., 2015). In addition, non-coding
RNAs, functional RNAs that are not translated, have the ability to regulate transcription,
splicing, and translation to regulate expression of genes (T. Chen & R Dent, 2013).
1.3.1.1. DNA methylation
DNA methylation involves the covalent attachment of a methyl group to the
cytosine base in a CpG dinucleotide context (Conerly & Grady, 2010) and follows a
broad spectrum of variation in levels and patterns in animals (Bird, 2002). Cytosine
methylation is generally associated with gene repression and heterochromatin formation
and is considered a stable epigenetic mark (Butler & Dent, 2013a). DNA methylation is
catalyzed by two classes of enzymes: the maintenance methyltransferase, DNA
methyltransferase 1 (DNMT1), and the de-novo methyltransferases which include DNA
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methyltransferase 3a (DNMT3A) and DNA methyltransferase 3b (DNMT3B) (Conerly &
Grady, 2010). In addition, DNMT3L aids in the stimulation of de-novo methyltransferase
activity of Dnmt3a (Dé Ric Ché, Lieber, & Hsieh, 2002). Patterns of cytosine
methylation established by these enzymes play important roles in chromatin organization
and gene regulation during organogenesis and gametogenesis (Goldberg et al., 2007).
DNA methylation is found throughout vertebrate genomes (Schübeler, 2015). Most of the
CpGs found in mammalian genomes are methylated (Field et al., 2018). When present in
gene bodies, DNA methylation aids in gene expression, whereas when found on distal
regulatory sequences, like enhancers, it promotes repression (Field et al., 2018). These
changes in gene expression are brought about by methylation-dependent interactions with
transcriptional activators and repressors (Conerly & Grady, 2010). In addition, DNA
methylation is critical for numerous cellular processes like the silencing of the repetitive
sequences, X-chromosome inactivation and genomic imprinting.
1.3.1.2. Histone modifications
Residues on histone tails can be post-translationally modified, which include
methylation, acetylation, sumoylation, phosphorylation, ubiquitination, de-amination,
adenosine diphosphate (ADP)-ribosylation and buturylation (Lawrence, Daujat, &
Schneider, 2016a). According to the “histone code” hypothesis histone modifications can
serve as recruitment sites for effector proteins (Jenuwein & David Allis, 2001). These
histone fold modifications can disrupt the interaction between nucleosomes, for example
acetylation of lysine 16 of histone H4 (H4K16ac) has been associated with a decrease in
chromatin compaction and increase in transcription (Lawrence, Daujat, & Schneider,
2016b). Whereas, histone modifications like trimethylation at lysine 20 of histone H4
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(H4K20me3) have been shown to enhance chromatin compaction (Lawrence et al.,
2016b). Some common histone modifications and their functions are listed in Table1.1.
Histone
Modification
H3K4me1/3
H3K9me3

Function
Enhancer Function/Gene
activation
Gene Repression

Enzyme

MLL3/MLL4
SUV39H1
CBP, P300,
H3K27ac
Gene Activation
GCN5
H3K27me3
Gene Repression
EZH2
H3K36me1-3
Gene Activation
SETD2
H3K36ac
Marks Active Promoters
GCN5
H4K16ac
Gene Activation
ATF2
H4K20me1
Gene Repression
SETD8
Table 1.1. Common histone modifications and their associated function in gene
regulation (adapted from (Zhao & Garcia, 2015)).
1.3.2. Chromatin modifiers
1.3.2.1. Histone methylation
Histone methylation has been observed on the lysine and arginine residues of H3
and H4. There are seven residues which can be mono, di or tri-methylated: lysine 4 of
histone H3 (H3K4), lysine 9 of histone H3 (H3K9), arginine 17 of histone H3 (H3R17),
lysine 27 of histone H3 (H3K27), lysine 36 of histone H3 (H3K36), arginine 3 of histone
H4 (H4R3) and lysine 20 of histone H4 (H4K20) (Lawrence et al., 2016a). Three main
protein families are responsible for catalyzing the methylation of these residues: the
PRMT1 family, the SET domain family and the DOT1/DOT1L containing non-SET
domain proteins (Martin & Zhang, 2009). The functional effects of lysine methylation in
terms of gene expression are context-dependent and can result in either activation or
inhibition of gene expression. For example, trimethylation at lysine 4 of histone H3
(H3K4me3) is associated with transcriptional elongation whereas trimethylation at lysine
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9 of histone H3 (H3K9me3) is linked with gene repression (Table 1.1) (Lawrence et al.,
2016a).
Methylated lysines can recruit other protein complexes collectively known as
“reader” proteins. Methylated lysine binding domains include the ankyrin repeat, the
plant homeodomain (PHD) finger, chromo, tudor, and malignant brain tumor (PWWP)
domains (Butler & Dent, 2013a).
Histone demethylases are responsible for catalyzing the demethylation of
methylated lysine and arginine residues on histone tails. Demethylation of lysine residues
is performed by two main families: jumonji-C domain-containing enzymes and amine
oxidases (Butler & Dent, 2013b). Jumonji domain-containing protein 6 (JMJD6),
peptidylarginine deiminase 4 (PADI4) and lysine-specific demethylases (KDMs) like
KDM3A, KDM4E KDM5C, and KDM6B are candidates for arginine demethylation
(Wesche et al., 2017). Because of conflicting reports in the literature regarding their
arginine demethylases activities, arginine demethylases have not been well characterized
(Wesche et al., 2017).
1.3.2.2. Histone acetylation
Histone acetyltransferases are enzymes that catalyze acetylation of histone tails
which results in effects on chromatin architecture and gene regulation. There are two
main families that contain histone acetyltransferase (HAT) domains: Gcn5 Nacetyltransferases and the MYST family of acetyltransferases (Lee & Workman, 2007).
There are other proteins which have the capacity to acetylate histones like E1A binding
protein p300 (EP300)/CREB binding protein (CBP), TATA-box binding protein
associated factor 1 (TAF1) and a number of nuclear coreceptors, however these are
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considered to be an orphan class of HAT enzymes because they do not harbor consensus
HAT domains (Lee & Workman, 2007). HATs can be recruited to their target loci by
specific proteins that contain tudor domain, PHD fingers, chromodomain, bromodomain,
and WD40 repeats. HATs play important roles in DNA repair and genome stability (Lee
& Workman, 2007). HATs also have non-histone acetylation targets for example
transformation-related protein 53 (P53) and general transcription factor IIB (TFIIB)
(Yang, 2004). Histone deacetylases (HDACs) catalyze the removal of acetyl marks from
histone residues (Butler & Dent, 2013a). Eleven HDACs are encoded by the mammalian
genome which share a conserved histone deacetylase domain and are divided into four
families: class I, IIa, IIb and IV (Haberland. Michael, Montgomery, & Olson., 2009).
1.3.3. MYST Family of acetyltransferases
The MYST family of acetyltransferases consists of five members: MOZ
(KAT6a), MORF(KAT6b), HBO1 (KAT7), TIP60 (KAT5) and MOF (KAT8)
(Avvakumov & Coˆte´, 2007). Proteins of the MYST family are characterized by the
presence of a MYST region, an acetyl co-enzyme A binding site and C2HC type zinc
finger motif (Valerio, Xu, Chen, et al., 2017). The presence of acetyl co-enzyme binding
site allows acetyl co-enzyme A to bind, which is required for the acetyltransferase
reaction (Sebastián & Mostoslavsky, 2017). The C2HC zinc finger motif aids in substrate
recognition and acetyltransferase activity (Akhtar & Becker, 2001).
1.3.3.1. KAT8
Lysine acetyltransferase 8 (KAT8) was initially identified as a regulator of dosage
compensation in flies (Su, Wang, Cai, Jin, & Chi-shing Cho, 2016.). KAT8 is responsible
for acetylation at H4K16 and Kat8 depletion can lead to abnormal gene transcription.
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Irregular expression of Kat8 and H4K16ac has been observed in various types of tumors
and cancer cells. HAT activity of KAT8 is necessary for MLL-AF9 tumorigenesis
(Valerio, Xu, Chen, et al., 2017). In addition, Kat8 is involved in lung cancer by
promoting S phase entry via regulation of H4K16ac. Kat8 is important for hematopoiesis
in newborn and adult mice, conditional deletion of Kat8 leads to hematopoietic failure
resulting in death of pups after 8-11 days of birth (Valerio, Xu, Eisold, et al., 2017).
Acetyltransferase activity of KAT8 was found to be important for its role in
hematopoiesis (Valerio, Xu, Eisold, et al., 2017). Transduction of Kat8 in Kat8conditionally deleted Lineage- cKit+ Sca1+ (LSK) cells, which consist of HSPCs, was
able to rescue colony forming potential in an in vitro methylcellulose based assay
whereas Kat8 with an inactive acetyltransferase domain was not able to rescue it
(Valerio, Xu, Eisold, et al., 2017).
1.3.3.2. KAT6A
Lysine acetyltransferase 6a (Kat6a) was originally identified as a fusion partner
with Cbp in translocation t(8;16)(p11;p13) which is found in 4-7/1000 cases of acute
myeloid leukemia (AML) (Borrow et al., 1996). In addition, fusions of Kat6a with
Ep300, Nuclear receptor coactivator 2 (Tif2) and developing brain homeobox 1 (Leutx)
have been found in other hematological malignancies (X.-J. Yang, 2015). KAT6A is
responsible for acetylation at lysine 9 of histone H3 (H3K9ac) at its target loci (Sheikh et
al., 2016). Loss of Kat6a in embryogenesis results in a reduction in the number of HSCs
(Katsumoto et al., 2006). Conditional deletion of Kat6a in bone marrow leads to a decline
in the number of HSCs and fewer of them were found to be in a quiescent stage as
compared to wild type controls (Sheikh et al., 2016). Fetal liver from mice with a
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catalytically inactive KAT6A histone acetyltransferase domain was also found to have a
diminished number of HSPCs (Perez-Campo, Borrow, Kouskoff, & Lacaud, 2009).
Hematopoietic progenitors containing catalytically inactive KAT6A have increased
expression of cyclin-dependent kinase inhibitor 2a (p16) and enhanced nuclear
localization of chromobox 3 (HP-1γ), markers for senescence (Perez-Campo et al., 2014).
This suggests that Kat6a is required for the maintenance of fetal and adult HSCs and that
histone acetyltransferase activity of KAT6A is important for this function by inhibiting
p16 expression.
1.3.3.3. KAT6B
Lysine acetyltransferase 6b (Kat6b) is a paralogue of Kat6a and shares more than
90% sequence similarity in functional domains. Homozygous Kat6b mutants survive
until three weeks of age and show craniofacial abnormalities and cerebral defects
(Thomas, Voss, Chowdhury, & Gruss, 2000). In a fluorescent reporter tagged
overexpression mouse model of Kat6b, high expression of Kat6b corresponded with cells
showing features of neural stem cells (Sheikh, Dixon, Thomas, & Voss, 2011) and
overexpression of Kat6b also resulted in increased neuronal production (Merson et al.,
2006). A mutation in Kat6b has been observed in a patient with Noonan syndrome which
involves hyperactivation of the mitogen-activated protein kinase (MAPK) pathway (Kraft
et al., 2011). KAT6B has been found to acetylate H3K23 (H3K23ac) (Sim O-Riudalbas
et al., 2015). Therefore, Kat6b is important for the function and generation of neural stem
cells. Although, the role of KAT6B in HSCs has not been studied yet, its importance in
neural stem cell function and its similarity to KAT6A suggests that KAT6B might also be
important for HSC function.
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1.4. Epigenetic regulation of HSC function
1.4.1 Role of histone writers and erasers in HSC differentiation
The dynamic nature of hematopoiesis relies on the tightly regulated process of
self-renewal and differentiation of HSCs (D. Hu & Shilatifard, 2016). Chromatin
modifying enzymes play important roles during hematopoiesis by regulating histone
modifications (Butler & Dent, 2013b). The importance of epigenetic regulators in
hematopoietic function is also demonstrated by the fact that mutations in these epigenetic
regulators are common in myeloid malignancies and also play a role in hematopoietic
transformation (Shih, Abdel-Wahab, Patel, & Levine, 2012). Epigenetic regulators
involve histone writers who perform the task of catalyzing the addition of posttranslational modifications (PTMs) on histones, whereas histone erasers remove those
histone modifications (Gillette & Hill, 2015). A number of histone writers and erasers
responsible for marks associated with both gene activation and repression have been
identified with respect to their role in HSC function.
Cbp, and its paralogue, p300, are histone lysine acetyltransferases responsible for
depositing the activating acetylation at lysine 27 of histone H3 (H3K27ac) mark (Chan et
al., 2011)(Tan, Nimer, Sun, Man, & Wang, 2015). Conditional deletion of Cbp in adult
bone marrow led to a decrease in HSPCs, an increase in myeloid and a decrease in the
lymphoid compartment, showing that Cbp is critical for differentiation of HSCs(Chan et
al., 2011). In addition, serial transplantation of conditionally deleted Cbp bone marrow
and HSCs had reduced reconstitution ability thus showing that Cbp is also important for
HSC self-renewal (Chan et al., 2011; Rebel et al., 2002).
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Histone deacetylases (HDACs) remove the acetylation mark deposited by
acetyltransferases like CBP. Studies involving the treatment of human CD34+ cells with
valproic acid, an HDAC inhibitor, have shown that inhibition of HDACs results in
increased proliferation of CD34+ cells as well as increased self-renewal of HSPCs as
observed by competitive repopulation assays (Zheng et al., 2005).
Histone lysine methyltransferases are responsible for catalyzing methylation on
lysine residues at histone tails. Methylation at lysine 4 and lysine 3 of histone 3 are the
most extensively studied among histone methylation marks (Greer & Shi, 2012). The
MLL family of histone methyltansferases is responsible for methylation of H3K4
residues which is associated with open chromatin (W. Yang & Ernst, 2017). Lysine
specific methyltransferase 2a (MLL1)-/- HSCs show a defect in self-renewal potential and
lack of success in engrafting recipients (W. Yang & Ernst, 2017). MLL3 is related to
MLL1 and both have been found to be mutated in acute lymphoid leukemia and acute
myeloid leukemia (C. Chen et al., 2014). Knockdown of lysine-specific methyltransferase
2c (MLL3) leads to an increase in LT-HSCs and a block in differentiation in a p53
background (C. Chen et al., 2014). Another member of the MLL family, lysine specific
methyltransferase 2d (MLL4), has also been found to be important for HSC function
(Santos et al., 2014). Conditional deletion of MLL4 in adult bone marrow leads to an
increase in the number of stem and progenitor cells (Santos et al., 2014). However, MLL4
deletion leads to decreased self-renewal capacity of HSCs which was shown by a
reduction in asymmetric division of HSCs and decreased competitive repopulation ability
of HSPCs (Santos et al., 2014). Apart from the MLL family, enhancer of zeste 2
polycomb repressive complex 2 subunit (EZH2) is responsible for trimethylation at lysine
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27 of histone H3 (H3k27me3) which is associated with gene inactivation (MochizukiKashio et al., 2011). Expression of Ezh2 decreases after the differentiation of HSPCs
(Abboud & Berman, 2013). Conditional deletion of Ezh2 in fetal liver leads to a decrease
in efficiency of repopulation ability in fetal liver, however, competitive repopulation of
adult bone marrow with Ezh2 deletion did not result in decrease in repopulation ability in
both primary and secondary transplants, showing that Ezh2 is more important for fetal
liver HSCs as compared to adults (Mochizuki-Kashio et al., 2011). Histone demethylases
play the role of removing methyl marks from methylated histone tails. Lysine specific
demethylase 1a (LSD1) is a histone demethylase that is responsible for removing
methylation from H3K4 residues (Kerenyi et al., 2013). Conditional deletion of Lsd1 in
adult mouse bone marrow leads to a reduction in stem cell self-renewal as well as a
reduction in myeloid progenitors (Kerenyi et al., 2013). Therefore, these studies show
that histone-modifying enzymes are important for various aspects in the function and the
differentiation of HSCs.
1.4.2. Role of enhancers in HSC differentiation
Enhancers are cis-regulatory DNA elements that regulate the transcription of
target genes (Halfon, 2019). Usually consisting of a few hundred base pairs in length,
enhancers function as a platform for recruitment of transcription and chromatinmodifying machinery which aids in the transcription of its target genes (Halfon, 2019).
Enhancers can perform these functions while being situated at long distances (> 1 Mb)
(Cico, Andrieu-Soler, & Soler, 2016a) and can be present both upstream or downstream
of their target genes as well as in introns of their target genes (Pennacchio, Bickmore,
Dean, Nobrega, & Bejerano, 2013).
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The first enhancer, SV40, was discovered around 40 years ago and was
responsible for increasing transcription of a β-globin gene in the rabbit by more than 200
fold (Banerji, Rusconi, & Schaffner, 1981). Since then, the important role of enhancers in
development and disease has been well established (Halfon, 2019). Enhancer-associated
chromatin goes through a number of changes that correlates with the activity of the
enhancer (Figure 1.6). Lineage determining transcription factors bind closed enhancer
associated chromatin to make it more accessible to histone methyltransferases which then
deposit monomethyl at lysine 4 of histone H3 (H3K4me1) on enhancer associated
chromatin (Heinz, Romanoski, Benner, & Glass, 2015). This marks the enhancer in a
primed state (Heinz et al., 2015). After this, histone acetyltransferases deposit H3K27ac
which marks the enhancer in an active state (Heinz et al., 2015).

Figure 1.6. Schematic for priming and activation of enhancers.
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In the context of hematopoiesis, studies involving focused investigation of gene
regulatory elements have demonstrated that enhancers play a role in hematopoietic
function (Bauer et al., 2013; Johnson et al., 2015). Whole-genome technologies have
accelerated the discovery of putative enhancers and have also allowed the study of a
larger number of enhancers. Using these approaches it was found that enhancers undergo
considerable changes in priming and activation status during differentiation of HSCs to
mature cells, the nature of these changes being dependent on the lineage type
(Choukrallah, Song, Rolink, Burger, & Matthias, 2015; Lara-Astiaso et al., 2014; Luyten,
Zang, Liu, & Shivdasani, 2014). These studies suggest that the enhancers which are
active in mature erythroid and myeloid cells become established in HSPCs (Lara-Astiaso
et al., 2014) whereas, the enhancers that are activated in mature lymphoid cells become
established in those mature cell types (Choukrallah et al., 2015; Lara-Astiaso et al.,
2014). This shows that there is a difference in the enhancer establishment and setting up
of the lineage-specific programs between erythroid, myeloid and lymphoid lineages.
1.4.3. Epigenetic changes in HSCs with age
HSCs undergo a variety of epigenetic changes with age involving DNA
methylation, histone modifications and expression of epigenetic regulators (Buisman &
Haan, 2019) which raises the possibility of the contribution of epigenetic regulators
towards HSC aging. There are overall changes in gene expression profiles with age
(Beerman et al., 2013; Sun et al., 2014; Wahlestedt et al., 2013). Specifically, the
expression of important epigenetic regulators declines with age (Sun et al., 2014).
Expression of genes associated with chromatin modification like Ezh2 and Cbx2 as well
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genes liked to DNA methylation like Tet methylcytosine dioxygenase 1 (Tet1) and Tet
methylcytosine dioxygenase 2 (Tet2) decreases with age (Sun et al., 2014).
In addition to variations in gene expression profiles, HSC aging involves changes in
levels and localization of histone modifications (Florian et al., 2012; Grigoryan et al.,
2018; Sun et al., 2014). Levels of gene activating marks H3K4me3 and H4K16ac
increase in old HSCs compared to young HSCs (Florian et al., 2012; Sun et al., 2014). On
the other hand, the number peaks of the repressive mark H3K27me3 do not change,
however the coverage of peaks becomes broader with age in HSCs (Sun et al., 2014).
Histone modifications like H4K16ac have found to distributed asymmetrically in the
nucleus of HSCs (Florian et al., 2012). Analysis of nuclear localization of histone
modifications showed that this polarity of H4K16ac and H3K27ac decreases significantly
whereas polarity of acetylation at lysine 8 of histone H4 (H4K8ac) and acetylation at
lysine 5 of histone H4 (H4K5ac) undergo modest decreases in polarity with age in HSCs
(Grigoryan et al., 2018). Restoration of polarity of H3K16ac by inhibition of CDC42 was
associated with functional rejuvenation of HSCs (Florian et al., 2012).
These studies suggest that gene-regulatory elements and epigenetic regulators are
important for function of HSPCs and that changes in epigenetic regulators and their
activities correlate with HSC aging. Which epigenetic regulators and gene regulatory
elements drive aging in HSCs and which related molecular pathways are perturbed in
aging by these epigenetic factors needs to be identified.
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CHAPTER 2
RESULTS
Hematopoiesis is a well-coordinated system of differentiation from HSCs to
mature cells which relies on precise changes in gene expression profiles at each point in
the differentiation continuum. Regulation of these gene expression profiles is dependent
on a dynamic collaboration between lineage-determining transcription factors, chromatinmodifying enzymes and cis-regulatory elements (Cico, Andrieu-Soler, & Soler, 2016b).
Misregulation of these chromatin-modifying enzymes and cis-regulatory elements can
disrupt the balance in the orchestration of precise gene expression profiles leading to
disease and aging-associated phenotypes. My thesis involves the identification and
characterization of gene regulatory elements and epigenetic regulators that are important
for HSPC differentiation to mature cells so that this knowledge can be utilized in
ameliorating the defects in the differentiation process due to aging.
Although genome-wide technologies have facilitated the identification of putative
enhancers, the number of functionally characterized enhancers is negligible compared to
the total number of putative enhancers. Activity of enhancers in the hematopoietic
progenitors has been observed to change with age (Poplineau et al., 2019). In the context
of lymphoid lineage, identification of functionally characterized enhancers is important
for developing novel therapeutic strategies to overcome the decline in lymphoid function
which is observed with aging. It has been reported that the majority of lymphoid specific
enhancers are established in mature cells and only a few are established in HSPCs
(Choukrallah et al., 2015; Lara-Astiaso et al., 2014). Therefore, I hypothesize that a few
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key enhancers which are established in HSPCs are important for commitment to the
lymphoid lineage. In the first part of results I outline the investigation of this hypothesis.
It is known that there is a decrease in the expression of key epigenetic factors and
changes in levels of histone modifications in LT-HSCs during aging in mice (Sun et al.,
2014) and humans (Adelman et al., 2019). However, precise molecular mechanisms
underlying changes in epigenetic regulators and hematopoietic aging have not been
elucidated yet. This serves as a barrier for developing novel therapeutic strategies for
ameliorating aging-associated hematopoietic decline. I hypothesized that changes in
expression/activity of key epigenetic regulators drive age-associated functional decline in
HSCs. The second part of the results section consists of an investigation of this
hypothesis.
2.1. Optimization of assay for in vitro differentiation of HSPCs to the lymphoid
lineage and identification and characterization of lymphoid specific enhancers
Enhancers are cis-regulatory elements that are capable of activating lineagespecific gene expression patterns (Heinz et al., 2015). This is supported by the
observation that distal cis-regulatory elements in mature lymphoid cells were found to be
enriched for motifs of transcription factors which are important for the lymphoid lineage
(Heinz et al., 2010). Although putative lymphoid specific enhancers have been identified
by genome-wide technologies, functional characterization of these enhancers is a barrier
for ameliorating the decline in production and function of lymphoid cell types which is
observed in aging (Dykstra et al., 2011; Miller, 1996; Rodrigues et al., 1997). Studies
have shown that the majority of lymphoid specific enhancers are established in mature
cell stages. I hypothesized that a few key enhancers that are established in HSPCs are
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important for commitment to lymphoid lineage. In this section I test this hypothesis by
optimizing culture conditions for in vitro OP9 co-culture of HSPCs to assess B-lymphoid
differentiation potential, followed by development of a knockout strategy for putative
lymphoid enhancers, ultimately employing these two techniques to characterize the
importance of putative lymphoid enhancers for differentiation of HSPCs to B-lymphoid
cells.
2.1.1 Optimization of co-culture conditions

Figure 2.1. Schematic for in vitro differentiation of HSPCs to B-lymphoid cells.
The in vitro assay for differentiation of HSPCs to B-lymphoid cells by co-culture
with OP9 stromal cells was adapted from Pietras et al. (Pietras et al., 2015a). For
optimization of starting cell number of OP9 cells appropriate for co-culture, I seeded
1000, 2000 or 5000 OP9 cells in flat-bottom 96-well plate on Day 0 of the assay (Figure
2.1). On day 1, 500 Lineage- cKit+ Sca1+ (LSK) cells, which consist of HSPCs, were
seeded on top of OP9 layer in OptiMEM supplemented with serum1(Hyclone defined;
AYM175301), serum 2 (Hyclone Defined; AB1016350) or serum 3(VWR) and stem cell
factor (SCF;), FMS tryosine like-3 ligand (FLT-3) and interleukin-7 (IL-7). On day 3 of
the assay half of the media was replaced with fresh media supplemented with SCF and
IL-7 (Figure 2.1). On day 5 of the assay half of the media was replaced with fresh media
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supplemented with IL-7 (Figure 2.1). Subsequently, the media was changed every 2-3
days with IL-7 supplementation. When the OP9 cell layer started to detach, the cells were
harvested by trypsinization and transferred to a new well in a 24-well plate with preseeded OP9 cells. Cells were analyzed by fluorescence-activated cell sorting (FACS) on
days 14, 17, 20 and 23 of the assay (Figure 2.1) and number of CD45+ cells and
percentage of CD19+ cells were used for determining the optimal conditions for the
assay.
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Figure 2.2. Optimization of OP9 seeding density, serum type and read-out time
point. 1000, 2000 or 5000 OP9 cells were seeded in 96-well plate, supplemented with
serum 1, serum 2 or serum 3 and analyzed by FACS on Day 14,17,20 and 21 of assay.
Total CD45+ cells obtained on day 14 (A), day 17 (C), day 20 (E), day 23 (G), Percentage
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of CD19+ and CD11b+ cells obtained on day 14 (B), day 17 (D), day 20 (F), day 23 (H).
Dots represent n =2 biological replicates.
As the purpose of this assay was to differentiate HSPCs to CD19+ B-lymphoid
cells, I determined which readout time point produced the highest percentage of CD19+
cells. Day 23 seemed to be most efficient for the production of CD45+ CD19+ cells
compared to the rest of the time points across all conditions (Figure 2.2). day 23 was used
as the reference time point to assess the effect of serum type and OP9 seeding density on
differentiation to B-lymphoid cells. Assays started with 1000 OP9 cells produced the
highest mean number of CD45+ cells across all serum types (Figure 2.2G) and also had
the highest percentage of CD19+ cells (Figure 2.2H) compared to assays started with
2000 and 5000 OP9 cells.
To ascertain the type of serum with the highest differentiation potential to CD45+
cells I compared total CD45+ cells obtained on day 23 with assays seeded at 1000 OP9
cells. I observed that cells supplemented with Serum 2 had the highest mean number of
CD45+ cells compared to Serum 1 and Serum 3 (Figure 2.2G).
To conclude, I observed that OP9 co-culture B-lymphoid differentiation assay
performs optimally when started with 1000 OP9 cells, supplemented with Serum 2 and
readout on day 23 of the assay.
2.1.2. Minimizing variability in OP9 co-culture assay
Although the conditions described the in last section were able to differentiate
HSPCs to CD19+ cells efficiently, I observed significant variation in the overall
differentiation ability between replicates for each condition (Figure 2.2G). In order to test
if this variation is dependent on the number of HSPCs that was used to start the assay, I
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seeded 10, 50, 100, 250 and 500 Lineage- cKit+ (LK) cells, which consist of HSPC and
lineage-committed progenitors, and compared their ability to differentiate to CD45+
CD19+ cells (Figure 2.3A). Assays started with all of the aforementioned LK cell
numbers produced CD19+ cells efficiently (Figure 2.3C); however, no correlation was
found between the total number of CD45+ cells obtained and the number of LK cells used
to start the assay (Figure 2.3B). This led me to hypothesize that the passaging conditions
involving trypsinization and transfer to a new well is the source of variability for this
assay.

Figure 2.3. Correlation between HSPC number and lymphoid differentiation ability
with OP9 stromal cells. (A) Schematic of lymphoid differentiation assay (B) Total
CD45+ cells obtained on day 23 of assay. (C) Percentage of CD19+ and CD11b+ cells
obtained on day 23 of assay.
To test this hypothesis, I performed the OP9 differentiation assay by seeding 1000
OP9 cells in a 96-well plate (Figure 2.4A) and 5000 OP9 cells in a 24-well plate (Figure
2.4D), followed by FACS analysis on day 12 without passaging during the assay. My
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results showed that the 96-well assay without passaging produced less CD45+ cells as
compared to an equivalent number of 500 LK cells readout on day 23 with passaging
(Figure 2.3B) and also less than 50% of CD45+ cells were CD19+ cells at the end of the
assay (Figure 2.4C). Although the 24-well assay without passaging produced a higher
number of CD45+ cells (Figure 2.4E) as compared to 96-well without passaging (Figure
2.4B) the percentage of CD19+ (Figure 2.4F) was still less than what had been obtained
with cells without passaging (Figure 2.3C), and the total number of CD45+ cells still
seemed variable (Figure 2.4D). Therefore, elimination of passaging did not mitigate the
variation in CD45+ numbers produced at end of assay and was also not efficient in
differentiation to CD19+ cells.
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Figure 2.4. Effect of passaging on differentiation ability in OP9 co-culture assay.
Schematic of assay without passaging in (A) 96-well and (D) 24-well plate. Total CD45+
cells obtained on day 12 of assay from (B) 96-well and (E) 24-well plate. Percentage of
CD19+ and CD11b+ cells obtained on day 12 of assay (C) 96-well and (F) 24-well plate.
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To further attempt to overcome the issue of heterogeneity arising due to the
trypsinization and harvest of cells during replating in this assay, I cultured 500 and 1000
LK cells with Transwells with readout on day 12 of the assay (Figure 2.5A). This method
of culture involved no contact between LKs and OP9 cells and transwells containing LK
cells were transferred to new wells on day 8 of the assay. There was still variability
between technical replicates of in total number of CD45+ cells produced (Figure 2.5B)
and was also inefficient at producing CD19+ cells (Figure 2.5C).

Figure 2.5. Effect of OP9-HSPC contact on differentiation ability in OP9 co-culture
assay. (A) Schematic of assay with transwells. (B) Total CD45+ cells obtained on day 12
of assay with 500 or 1000 starting HSPCs. (C) Percentage of CD19+ and CD11b+ cells
obtained on day 12 of assay with 500 or 1000 starting HSPCs.
Therefore, out of all the culture conditions that I have investigated, culture for 23
days with serum 2 starting with 1000 OP9 cells with passaging seem to be the most
optimal conditions for efficient differentiation of HSPCs to B-lymphoid CD19+ve cells
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and my experiments also suggest that this assay is more suitable for qualitative rather
than quantitative analysis.
2.1.3. Identification and characterization of lymphoid specific enhancers
2.1.3.1. In silico identification of putative lymphoid specific enhancers
The goal of this part of the study was to test the hypothesis that lymphoid specific
enhancers established in HSPCs are important for commitment to lymphoid lineage. I
tested this hypothesis by identifying and characterizing cis-regulatory elements that were
functionally important for the commitment of HSPCs to B-lymphoid lineage. To test this
hypothesis, I utilized a published catalog of putative enhancers in the hematopoietic
system (Lara-Astiaso et al., 2014). Lara-astiaso et al identified these putative enhancers
by using levels of H3K4me1, di-methylation at lysine 4 of histone H3 (H3K4me2),
H3K27ac and expression of nearest genes from hematopoietic stem, progenitor and
mature cells (Lara-Astiaso et al., 2014). To identify B-lymphoid specific enhancers from
this catalogue I used H3K4me1 levels (<25 was considered not primed; >25 was
considered primed) to assess status of priming and H3K27ac levels (<25 was considered
inactive; >50 was considered active) to assess status of activation at a particular enhancer
as defined by Lara-Astiaso et al, 2014.
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Enhancer Type A

LT-HSC

ST-HSC

MPP

CLP

B

H3K4me1

>50

>50

>50

>50

>50

H3K27ac

<25

<25

<25

>25

>25

Enhancer Type B

LT-HSC

ST-HSC

MPP

CLP

B

H3K4me1

>50

>50

>50

>50

>50

H3K27ac

<25

<25

<25

<25

>25

Enhancer Type C

LT-HSC

ST-HSC

MPP

CLP

B

H3K4me1

<25

<25

>50

>50

>50

H3K27ac

<25

<25

<25

>25

>25

Enhancer Type D

LT-HSC

ST-HSC

MPP

CLP

B

H3K4me1

<25

<25

>50

>50

>50

H3K27ac

<25

<25

>25

>25

>25

Enhancer Type E

LT-HSC

ST-HSC

MPP

CLP

B

H3K4me1

<25

<25

<25

<25

>50

H3K27ac

<25

<25

<25

<25

>25

Table 2.1. Criteria for identification of putative lymphoid specific enhancers.
Numbers represent processed read counts for H3K4me1 and H3K27ac ChIP-seq data
sets.
Therefore, by using levels of H3K4me1 and H3K27ac ChIP-seq data in HSCs,
MPPs, CLPs, and B-cells (Table 2.1), I mined for enhancers that would be predicted to be
primed and activated at various stages during differentiation from HSCs. My results
revealed a total of 665 putative enhancers which were active in B-cells and which can be
divided into 5 broad categories: Type A, Type B, Type C, Type D and Type E (Figure
2.7).
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Figure 2.6. Graphical representation of priming and activation status of putative
enhancers active in B-cells.
Enhancers in Type A and Type B both got primed in HSCs however, Type A
enhancers got activated in CLPs, whereas Type B enhancers got activated in B-cells
(Figure 2.6). Because Type A and Type B enhancers got primed at HSCs these enhancers
were denoted as “Pre-disposed enhancers” and contained 4 and 13 enhancers
respectively. Type C and Type D enhancers both got primed in MPPs (Figure 2.6). Type
C enhancers became activated in CLPs, whereas Type D enhancers became activated in
MPPs (Figure 2.6). The final category, Type E, consisted of enhancers that got primed
and activated in B-cells. Type C, Type D and Type E enhancers were denoted as “Denovo Enhancers” because these got established or primed In MPP or later stages and
contained 1, 1 and 646 enhancers respectively (Figure 2.6). Since I was interested in
enhancers which are important for commitment to lymphoid lineage I decided to pursue
enhancers in categories Type A, Type B, Type C and Type D for validation. One
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enhancer was randomly selected from each category (Enhancer A1, Enhancer B1,
Enhancer C, Enhancer D) for initial functional characterization (Table 2.2).
Enhancer Type
Chromosome #
Coordinates
Enhancer A1
5 37059418-37061418
Enhancer B1
10 98591289-98593289
Enhancer C
8 55069106-55071106
Enhancer D
1 16748743-16750743
Table 2.2. Genome loci of enhancers short-listed for functional characterization.
2.1.3.2. Strategy for ex vivo CRISPR/Cas9 mediated enhancer knockout in primary
cells
To characterize putative B-lymphoid enhancers identified in Section 2.1.3.1, I
employed CRISPR/Cas9 mediated knockout strategy. It consisted of performing
knockout of each putative enhancer by using targeting 2 sgRNAs flanking each enhancer
(Table 3.3). Initially, I employed a strategy consisting of delivery of Cas9 expressing
plasmid in primary cells by lentiviral transduction.
2.1.3.2.1. Determining the efficiency of lentiviral transduction of Cas9
For optimization of gene delivery of Cas9 by lentiviral transduction, I used 3rd and
4th generation systems of lentiviral packaging. I prepared lentivirus containing
pLentiCRISPR-EGFP, which expresses Cas9 along with GFP, using 3rd and 4th
generation lentiviral systems (Figure 2.7) and transduced whole bone marrow (BM)
mononuclear cells from wildtype C57BL/6J mice. 3rd generation lentiviral systems
consist of two viral packaging plasmids: one encodes Gag/Pol and second encodes Rev
(“Lentiviral guide,” 2019). Whereas the 4th generation consists of 4 packaging plasmids
with each containing a component for viral assembly (“Fourth-generation lentiviral
packagin overview,” 2019).
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Figure 2.7. Schematic of generation of viral supernatant containing pLentiCRIPSREGFP with 3rd and 4th generation lentiviral packaging systems.
Cells were analyzed with FACS analysis after 48 hours post-transduction (Figure
2.8A). My results showed that the transduction efficiency from both of the packaging
system was almost similar and was considerably low (< 0.5% GFP cells) to obtain a
sufficient number of transduced cells for downstream analysis (Figure 2.8B). Since
transduction of the 4th generation system was not lower than the 3rd generation system
and 4th generation system is safer than 3rd generation, I selected the 4th generation
packaging system for use in further experiments.
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Figure 2.8. No difference in transduction efficiency of whole BM cell transduced
with lentivirus packaged with 3rd and 4th generation packaging systems. (A)
Schematic of transduction of whole BM cells (B) Transduction efficiency (%GFP+) cells
obtained after transduction with 3rd generation and 4th generation virus.
To improve the transduction efficiency, I switched to a more homogenous
population, LSKs, as compared to whole bone marrow mononuclear cells and transduced
twice (once at day 0 and a second time 24 hours after the 1st transduction) (Figure 2.9A).
However, I still obtained a negligible transduction efficiency (Figure 2.9B).

Figure 2.9. Effect of number of transductions on transduction efficiency (A)
Schematic for transduction of whole BM cells with viral supernatant containing
pLentiCRISPR-EGFP. (B) Transduction efficiency (%GFP+ cells) obtained after two
consecutive transductions of LSK cells.
Next, I investigated the effect of the cell type and the amount of virus used for
transduction on transduction efficiency. I transduced LSK cells with 10%, 50% and 75%
virus by volume. Transduction was repeated after 24 hours. I analyzed the cells by FACS
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48 hours post-transduction (Figure 2.10A). My results showed that the cells transduced
with 10%, 50% and 75% virus produced approximately 0.17%, 0.56% and 0% GFP+ cells
(Figure 2.10B).

Figure 2.10. Effect of viral concentration by volume of culture media on
transduction efficiency (A) Schematic for transduction of LSKs with viral supernatant
containing pLentiCRISPR-EGFP using different viral concentrations. (B) Transduction
efficiency (%GFP+) cells obtained after transduction with 10%, 50% and 75% by volume
virus concentrations.
After this, I prepared concentrated virus containing pLentiCRISPR-EGFP by
ultracentrifugation of viral supernatant, and transduced LSK cells with 0.5%, 10% and
50% virus by volume, followed by FACS analysis 48 hours post-transduction (Figure
2.11A). However, my results showed no GFP+ cells with these conditions (Figure 2.11B).
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Figure 2.11. Effect of concentrated virus on transduction efficiency. (A) Schematic
for transduction of LSKs with concentrated viral supernatant containing pLentiCRISPREGFP using different viral concentrations. (B) Transduction efficiency (%GFP) cells
obtained after transduction with 0.5%, 10% and 50% by volume virus concentrations.
Toxicity due to concentrated virus could be responsible for these results.
Overall, Cas9 delivery by lentiviral transduction seemed an inefficient method for
gene transfer in primary hematopoietic cells. Therefore, I concluded that this method was
not appropriate for validating B-lymphoid specific enhancers.
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2.1.3.2.2. Knockout by electroporation of in vitro transcribed sgRNA and Cas9
protein

Figure 2.12. Knockout of enhancer B1 results in a reduction in the percentage of
CD19+ cells. (A) Schematic for electroporation of Cas9-sgRNA RNPs in LK cells and
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assessment of differentiation potential by OP9 co-culture. (B) Verification of knockout.
(C) Total CD45+ cells and (D) Percentage of CD19+ and CD11b+ cells obtained on day 23
of assay.
Efficient CRIPSR/Cas9 mediated gene editing involving gene delivery by
electroporation of ribonucleoprotein (RNP) complexes containing Cas9 protein and
sgRNAs has been reported in the literature (Gundry et al., 2016). Electroporation, in this
case, employed the neon transfection system (Invitrogen), which allows electroporation
of low input cells, which was suitable for my experiments. For preliminary experiments,
one enhancer from each of the shortlisted enhancer categories was selected for validation.
In addition, spleen focus forming virus (SFFV) proviral integration oncogene (Pu.1) was
selected as a positive control because of its importance in the differentiation of HSCs to
lymphoid progenitors (Iwasaki et al., 2005). sgRNAs were designed flanking each
enhancer and flanking exons 4 and 5 of Pu.1 gene using Benchling. Oligos containing
sgRNAs linked to the T7 promoter were designed and gRNA scaffold was amplified
from pX458 plasmid using these oligos, followed by in vitro transcription to produce
sgRNAs as described (Gundry et al., 2016).
LK cells were isolated from wildtype C57BL/6J young mice and cultured in the
presence of SCF and TPO for three hours. RNP complexes for each enhancer and Pu.1
were made with 1 ug of Cas9 and 0.5ug of each of two flanking sgRNAs for each
condition. These RNPs were electroporated in LK cells after three hours of culture, and
cells were plated into the OP9 lymphoid differentiation assay. Cells were analyzed by
FACS analysis on Day 23 and CD45+ cells were sorted for genomic DNA extraction to
determine knockout efficiency (Figure 2.12A). I observed efficient knockout of target
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regions in almost all conditions (Figure 2.12B). Total CD45+ cells were not significantly
different between positive and negative controls and enhancer knockout cells (Figure
2.12C). There was a slight decrease in the percentage of CD19+ cells from Enhancer B1
knockout cells (Figure 2.12D) which was similar to change observed from the positive
control (Pu.1) although the result was not statistically significant
Therefore, electroporation of RNP complexes is an efficient method for gene
targeting in primary HSPCs. In addition, this preliminary data shows that knockout of
enhancer B1 in HSPCs shows a subtle reduction in CD19+ cells as compared to negative
controls. However, this will need to be reproduced in a more robust assay to draw
definite conclusions.
2.2. Aging-Associated decrease in the histone acetyltransferase KAT6B is linked to
myeloid-biased hematopoietic stem cell differentiation with age
HSCs give rise to all mature blood cells. However, with age, cell-intrinsic
changes within HSCs contribute to aging-associated hematopoietic decline such as
increased HSC frequency, enhanced differentiation toward myeloid cells, and decreased
ability to return to quiescence after activation (Verovskaya, Dellorusso, & Passegué,
2019). Molecular features that contribute to these phenotypes include loss of cell polarity,
impaired DNA damage repair, increased production of reactive oxygen species (ROS),
and declines in mitochondrial function (Verovskaya et al., 2019). In addition, previous
studies support the occurrence of epigenetic drift in aged HSCs. This involves decreased
expression of key epigenetic regulators, a global increase in DNA methylation (Beerman
et al., 2013; Sun et al., 2014), and altered levels of histone H3 lysine 4 trimethylation
(H3K4me3) and lysine 27 trimethylation (H3K27me3) in both aged murine and human
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HSCs (Adelman et al., 2019; Sun et al., 2014). Moreover, diminished levels and polarity
of histone H4 lysine 16 acetylation (H4K16ac) is associated with loss of regenerative
capacity and gain of myeloid lineage skewing in aged LT-HSCs (Florian et al., 2012).
While these studies support involvement of epigenetic regulatory processes in HSC
aging, there remains a lack of comprehensive knowledge of the extent to which
epigenetic alterations are linked to aging-associated changes in HSC function. Therefore,
the goal of this study was to identify novel role of epigenetic regulators in the context of
myeloid skewed differentiation of HSCs.
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Figure 2.13. Candidate screen for epigenetic regulators of myeloid versus Blymphoid differentiation. (A) Schematic of candidate selection criteria to identify
chromatin regulatory genes involved in myeloid versus B-lymphoid differentiation of
HSPCs. GMP; granulocyte-macrophage progenitors, CLP; common lymphoid
progenitors. (B) GO enrichment analysis of 2,766 genes identified as differentially
expressed between GMP versus CLP. (C) Relative expression of shRNA target genes
following knockdown in NIH/3T3 cells. Bars represent mean of n = 3 technical
replicates.
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To identify epigenetic regulators that have a functional role in aging-associated
myeloid lineage-biased differentiation of HSCs a graduate student in our lab, Sneha
Borikar, conducted an in vitro shRNA screen. Using gene expression commons (GEXC)
(Seita et al., 2012), she identified 2,766 differentially expressed genes between
granulocyte macrophage progenitors (GMPs) and common lymphoid progenitors (CLPs)
(Figure 2.13A), which are committed progenitors for the myeloid and lymphoid lineages,
respectively (Motonari, 2013). Among these 2,766 differentially expressed genes, gene
ontology (GO) enrichment analysis of Reactome pathways (Ashburner et al., 2000; Mi et
al., 2017; The Gene Ontology Consortium 2019) revealed significant enrichment of
chromatin modifying enzymes (P = 0.000158, FDR = 0.00111). The 40 most enriched
genes encoding chromatin modifying enzymes were further filtered to 30 genes based on
overlap with the GO annotation “regulation of gene expression” (GO:0010468) (Figure
2.13B). Lastly, this gene list was filtered to include those with commercially available
shRNA constructs with verified knockdown in murine cell lines, resulting in 16 genes
(Table 2.3).
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Gene Symbol

Gene Name

Kat6b

K(lysine) acetyltransferase 6B

Kmt5a

lysine methyltransferase 5A

Tbl1x

transducin (beta)-like 1 X-linked

Kdm5b

lysine (K)-specific demethylase 5B

Ncor2

nuclear receptor co-repressor 2

Suv39h2

suppressor of variegation 3-9 2

Mta3

metastasis associated 3

Carm1

coactivator-associated arginine methyltransferase 1

Dot1l

DOT1-like, histone H3 methyltransferase (S. cerevisiae)

Kmt2e

lysine (K)-specific methyltransferase 2E

Arid1a

AT rich interactive domain 1A (SWI-like)

Kdm5c

lysine(K)-specific demethylase 5C

Smarcc2

SWI/SNF related, matrix associated, actin dependent regulator of
chromatin, subfamily c, member 2

Sap30l

SAP30-like

Jmjd6

jumonji domain containing 6

Padi2

peptidyl arginine deiminase, type II

Table 2.3. Sixteen chromatin regulatory genes for shRNA screening identified using
an unbiased differential expression approach.
To begin functional screening, shRNA expression plasmids for six of these 16
genes were obtained. For negative and positive controls, she used a scrambled shRNA57

expressing non-targeting control (NTC) vector and a shRNA vector targeting CREBbinding protein (Crebbp), respectively. Conditional knockout of Crebbp is known to
cause loss of HSPCs and result in myeloid-biased hematopoiesis (Chan et al., 2011). In
addition, shRNA constructs were obtained for eight genes hypothesized to regulate
lineage differentiation using a candidate gene approach (Table 2.4). After cloning, she
validated reduced target gene expression from each of these shRNA constructs in murine
3T3 cell lines (Figure 2.13C).

Gene Symbol

Gene Name

Rnf40

ring finger protein 40

Atxn7l3

ataxin 7-like 3

Prdm16

PR domain containing 16

Cxxc1

CXXC finger 1 (PHD domain)

Dach1

dachshund family transcription factor 1

Atxn7l1

ataxin 7-like 1

Ndn

necdin

Ezh1

enhancer of zeste 1 polycomb repressive complex 2 subunit

Table 2.4. Eight chromatin regulatory genes for shRNA screening identified using a
candidate gene approach.
To perform the in vitro shRNA screen, HSCs would seem to be the most
appropriate cell type however, we have observed in our lab (data not shown) that HSCs
do not perform well in B-lymphoid CFU assays. MPP4 cells have both lymphoid and
myeloid differentiation potential (Pietras et al., 2015a) and, in contrast to LT-HSCs, have
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efficient clonal in vitro differentiation capacity giving rise to both lymphoid and myeloid
cells (Young et al., 2016). Thus, we chose to utilize lymphoid-primed multipotent
progenitor cells (MPP4) as our starting cell population to conduct this screen. MPP4 (LinSca+ c-Kit+ Flt3+) cells were isolated by FACS from young adult (8-10 weeks old) mice,
transduced with lentiviral particles containing individual shRNA expression plasmids,
and cultured for two days with growth factors that we previously identified as supporting
both lymphoid and myeloid differentiation from this population (Young et al., 2016b)
(Figure 2.14A).
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Figure 2.14. Functional shRNA screen for epigenetic regulators of myeloid versus Blymphoid differentiation identifies Kat6b. (A) Schematic of experimental design to test
epigenetic regulatory gene candidates using shRNA-mediated knockdown in lymphoidprimed multipotent progenitor cells (MPP4) and colony-forming unit (CFU) assays. (B)
60

(Top panel) Frequency of myeloid and B-lymphoid colonies out of total colonies and
(Bottom panel) CFU cloning efficiency calculated as the total number of myeloid and Blymphoid colonies following shRNA knockdown of the indicated target genes divided by
the total number of myeloid and B-lymphoid colonies in NTC. NTC; non-targeting
control. Bars represent mean ± SEM of n ³ 2 biological replicates. *P < 0.05; **P < 0.01;
***P < 0.001 by two-way ANOVA and Dunnett’s multiple comparisons test or one-way
ANOVA and Holm-Sidak’s multiple comparisons test.
After two days, GFP-expressing cells were isolated by FACS and plated into parallel
myeloid and B-lymphoid colony-forming unit (CFU) differentiation assays. To identify
genes responsible for myeloid versus B-lymphoid differentiation, I sought genes whose
knockdown produced a significant change in the proportion of myeloid relative to Blymphoid colonies while maintaining overall cloning efficiency. Relative to NTC, I found
that knockdown of our positive control Crebbp resulted in a near-complete loss of CFU
capacity and the residual colonies that formed were predominantly myeloid (Figure
2.14B), consistent with the expected phenotype of Crebbp loss (Chan et al., 2011). In two
out of the 14 shRNA constructs evaluated, targeting Kat6b and Rnf40 (ring finger protein
40), I observed a significant increase in the proportion of myeloid relative to B-lymphoid
colonies (Figure 2.14B, Top panel). Of these, only knockdown of Kat6b was found not to
alter overall cloning efficiency (Figure 2.14B, Bottom panel) and thus was pursued as a
candidate epigenetic regulator of aging-associated myeloid lineage bias.
2.2.1. KAT6B decreases at the transcript and protein level in aged LT-HSCs
As the goal of this study was to gain insight into the functional role of Kat6b in
aging-associated myeloid lineage-biased differentiation of HSCs, I sought to determine if
Kat6b is abundantly expressed within the HSCs and how this expression may be altered
in aging. I isolated LT-HSCs (Lin- Sca+ c-Kit+ CD150+ CD48-) by FACS from young (2-4
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month) and aged (20-23 month) mice. By real-time PCR, I observed that the Kat6b
transcript is expressed in LT-HSCs and that its expression decreases 2.8-fold with age in
LT-HSCs (Figure 2.15A).

Figure 2.15. KAT6B is decreased in aged LT-HSCs. (A) Relative expression of Kat6b
in LT-HSCs isolated from young (2-4 month) and aged (20-23 month) mice. Bars
represent mean ± SEM of n ³ 3 biological replicates. *P < 0.05 by unpaired t test. (B)
Representative immunofluorescence images of KAT6B and DAPI in LT-HSCs isolated
from young and aged mice. Scale bar equals 5 µm. (C) Violin plots of mean fluorescence
intensity (MFI) of KAT6B in LT-HSCs isolated from young and aged mice. Solid lines
indicate median and dotted lines indicate quartiles. Data points include n = 17-64
individual cells sampled from n = 4 biological replicate animals. ***P < 0.001 by
unpaired t test.
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Previous work comparing transcriptional changes between young and aged mouse LTHSCs found a 1.2-fold decrease in Kat6b expression in aged LT-HSCs (FDR = 0.0413)
(Sun et al., 2014) and a recent study comparing human HSPCs (Lin- CD34+ CD38-)
isolated from young (18-30 year-old) and aged (65-75 year-old) individuals (Adelman et
al., 2019) identified that KAT6B transcript decreases 1.2-fold in aging (Padj = 0.0397),
supporting my finding that Kat6b levels decrease with age in HSCs. To analyze KAT6B
at the protein level, I immuno-stained LT-HSCs isolated by FACS from young and aged
mice with an antibody against KAT6B and the nuclear stain DAPI (Figure 2.15B). I
observed that the mean fluorescence intensity (MFI) of KAT6B in LT-HSCs isolated
from aged mice is significantly lower than in young mice (Figure 2.15C). Together, my
results show that KAT6B is significantly decreased at both the transcript and protein
levels in aged LT-HSCs.
2.2.2. Knockdown of Kat6b in LT-HSCs causes myeloid-biased in vitro
differentiation in CFU assays
To evaluate the functional consequence of reduced expression of Kat6b as
observed in aged LT-HSCs, I utilized a shRNA knockdown approach. LT-HSCs isolated
from young mice were transduced with lentiviral particles containing NTC or one of two
Kat6b shRNA expression plasmids and cultured for two days with growth factors
supporting LT-HSC maintenance (Figure 2.16A) (Holmfeldt et al., 2016). After two days,
GFP+ cells were isolated by FACS and evaluated for in vitro myelo-erythroid
differentiation using CFU assays. From the resultant colonies, I determined that Kat6b
transcript was reduced by 4.8-fold and 1.5-fold using Kat6b shRNA1 (sh1) and Kat6b
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shRNA2 (sh2), respectively (Figure 2.16B). The total number of colonies was not
significantly altered in sh1 or sh2 compared to NTC (Figure 2.16C).

Figure 2.16. Kat6b knockdown alters myeloid differentiation of LT-HSCs in vitro.
(A) Schematic of experimental design to knockdown Kat6b in LT-HSCs and assess
differentiation in the myeloid CFU assay. (B) Relative expression of Kat6b in colonies
following shRNA-mediated knockdown of Kat6b using two independent hairpins (sh1 or
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sh2) or NTC. Bars represent mean ± SEM of n ³ 3 biological replicates. ***P < 0.001 by
one-way ANOVA and Holm-Sidak’s multiple comparisons test. (C) Total number of
colonies produced and (D) colony subtype distribution from 200 GFP+ cells posttransduction of LT-HSCs. CFU-M; macrophage, CFU-GM; granulocyte-macrophage,
CFU-GEMM; granulocyte-erythrocyte-macrophage-megakaryocyte. Dots denote
biological replicates and bars represent mean ± SEM of n ³ 3 biological replicates. *P <
0.05; ***P < 0.001 by two-way ANOVA and Dunnett’s multiple comparisons test. (E)
Total number of colonies produced upon passage of 30K cells harvested from the primary
CFU assay. Dots denote biological replicates and bars represent mean ± SEM of n = 3
biological replicates.
However, differences were observed with respect to colony composition, determined
based upon cellular morphology within each colony to distinguish macrophage-only
(CFU-M), granulocyte-macrophage (CFU-GM) and granulocyte-erythrocytemacrophage-megakaryocyte (CFU-GEMM) colonies. Upon knockdown of Kat6b, I
observed a significant increase in the number of CFU-GM colonies and a significant and
consistent decrease in the number of CFU-GEMM colonies (Figure 2.16D), consistently
with both shRNA constructs. In addition, I investigated the effect of Kat6b knockdown
on colony replating capacity for further assessment of myeloid differentiation potential.
While NTC colonies did not replate past passage three, I observed that Kat6b knockdown
colonies replated to passage five, representing an increase in CFU replating capacity
(Figure 2.16E). Together, my results demonstrate that knockdown of Kat6b results in
myeloid-biased in vitro differentiation from LT-HSCs and increased serial replating
capacity of the resultant myeloid progenitor cells.
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2.2.3. Knockdown of Kat6b in LT-HSCs causes myeloid-biased differentiation in vivo
To evaluate the functional consequence of reduced levels of Kat6b in LT-HSCs in
vivo, I transduced LT-HSCs with Kat6b sh1 or NTC and transplanted GFP+ cells into
lethally irradiated B6.CD45.1 recipient mice (Figure 2.17A).
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Figure 2.17. Kat6b knockdown alters myeloid and erythroid differentiation of LTHSCs in vivo. (A) Schematic of experimental design to knockdown Kat6b in LT-HSCs
and assess hematopoietic reconstitution in lethally irradiated recipient mice compared to
NTC-transduced LT-HSCs. (B) Frequency of donor-derived cells (CD45.2+ GFP+) in the
peripheral blood (PB) of recipient mice, (C) myeloid cells (CD11b+ve) within donorderived PB cells (CD45.2+ GFP+), and (D) erythroid cells (Ter119+) within donor-derived
PB cells (GFP+) at 1 month (1mo) post-transplant. Each dot represents one recipient
mouse. Lines represent mean ± SEM of n ³ 7 biological replicates. *P < 0.05; ***P <
0.001 by Mann-Whitney test. (E) Frequency of B (B220+) and T (CD3e+) cells within
donor-derived PB cells (CD45.2+ GFP+) at one month post-transplant. Each dot
represents one recipient mouse. Lines represent mean ± SEM of n ³ 7 biological
replicates. P values calculated by unpaired t test.

In total, 15 recipient mice were transplanted with NTC-transduced cells and 16
recipient mice were transplanted with Kat6b sh1-transduced cells. From these, 7/15
(46%) and 8/16 (50%) were found to have multilineage engraftment above a threshold of
0.1% donor-derived peripheral blood cells at one-month post-transplant. At this time
point, donor-derived engraftment (% CD45.2+ GFP+) was not significantly different
between NTC and Kat6b sh1 (Figure 2.17B). However, mice transplanted with Kat6b
knockdown LT-HSCs had a significant increase in the proportion of donor-derived
myeloid cells in the peripheral blood as compared to NTC (Figure 2.17C). In addition,
there was a significant decrease in donor-derived erythroid cells in the peripheral blood
of mice transplanted with Kat6b knockdown LT-HSCs compared to NTC (Figure 2.17D).
A trend toward decreased frequency of donor-derived B and T lymphocytes in Kat6b
knockdown compared to NTC did not reach statistical significance (P = 0.0765 and P =
0.1984, respectively) (Figure 2.17E).
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At four months post-transplant, 3/15 (20%) and 3/16 (18.8%) of recipients were found to
have sustained multilineage engraftment above a threshold of 0.1% donor-derived
peripheral blood cells (Figure 2.18A).
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Figure 2.18. Multilineage engraftment of LT-HSCs following Kat6b knockdown. (A)
Frequency of donor-derived cells in the peripheral blood (PB) of recipient mice at 4mo
post-transplant. Each dot represents one recipient mouse. Lines represent mean ± SEM of
n = 3 biological replicates. (B) Limiting dilution analysis of repopulating cell frequency
from NTC or Kat6b-transduced LT-HSCs at 4mo post-transplant. (C) Frequency of
myeloid (CD11b+), erythroid (Ter119+), B (B220+) and T (CD3e+) cells within donorderived PB cells at four months post-transplant. Each dot represents one recipient mouse.
Lines represent mean ± SEM of n = 3 biological replicates. P values calculated by MannWhitney test.
These data were utilized to calculate repopulating cell frequency by limiting
dilution analysis (Y. Hu & Smyth, 2009). In the NTC group, the repopulating cell
frequency was calculated to be 1/1170 (1/3644 to 1/376; 95% Confidence Interval (CI)),
similar to the repopulating cell frequency in Kat6b knockdown (1/6720, 1/1683 to 1/422;
95% CI) (Figure 2.18B). In addition, frequency of donor-derived lymphocytes, erythroid
and myeloid cells showed similar trends at 4-month transplant as were observed at 1month post-transplant in Kat6b knockdown compared to NTC, but did not reach
statistical significance (Figure 2.18C). Together, these results show that knockdown of
Kat6b causes myeloid-biased differentiation from LT-HSCs in vivo without altering
repopulation capacity.
2.2.4. Knockdown of Kat6b in LT-HSCs decreases multilineage priming and
promotes expression of inflammation-associated gene signatures
To investigate the molecular mechanisms underlying myeloid-biased
differentiation after Kat6b knockdown, I transduced LT-HSCs with NTC or Kat6b sh1
and performed RNA-seq on sorted GFP+ cells. Unsupervised clustering separated NTC
and Kat6b knockdown samples (Figure 2.19A). 252 significantly differentially expressed
genes (FDR < 0.05) were identified, out of which 127 genes were upregulated and 125
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genes were downregulated in Kat6b knockdown compared to NTC (Figure 2.19B). Kat6b
itself was found to be downregulated by 1.2-fold in Kat6b knockdown compared to NTC
samples. In addition, I observed downregulation of Aldh3a1 (aldehyde dehydrogenase
family 3), loss of which impairs B cell development and HSC function (Gasparetto et al.,
2012) and Apoe (apolipoprotein E), loss of which has been demonstrated to cause
monocytosis and neutrophilia in mice (Murphy et al., 2011).
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Figure 2.19. Kat6b knockdown alters gene expression programs critical for
multilineage differentiation. (A) PCA plot showing unsupervised clustering of gene
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expression profiles from Kat6b sh1 (n = 3) and NTC (n = 3). Each color represents a set
of biological replicate samples. (B) Volcano plot showing log fold changes of genes
against -log10 of FDR. Points in red highlight genes with FDR < 0.05. (C) Gene set
enrichment analysis (GSEA) of genes upregulated in young versus aged LT-HSCs (Sun
et al., 2014). Red denotes NTC and blue denotes Kat6b sh1. (D) Gene set enrichment
analysis (GSEA) of genes upregulated in aged versus young LT-HSCs (Sun et al., 2014).
Red denotes NTC and blue denotes Kat6b sh1. (E) Normalized enrichment score from
GSEA analysis of the indicated datasets in Kat6b sh1 versus NTC. Black bars indicate
FDR < 0.05, white bars indicate FDR > 0.05. (F) Top gene ontology (GO) terms enriched
in genes found to be significantly upregulated in Kat6b sh1 versus NTC (fold change > 2
and P < 0.05). (G) Top gene ontology (GO) terms enriched in genes found to be
significantly downregulated in Kat6b sh1 versus NTC (fold change > 2 and P < 0.05).
To test the hypothesis that Kat6b knockdown alters expression of gene programs
associated with aging and differentiation of LT-HSCs, we performed gene set enrichment
analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005). Gene set enrichment
analysis compares the expression of query gene list between our control or experiment
samples and then ranks the genes based on enrichment in either the control or
experimental samples. Comparing our RNA-seq data to LT-HSC aging gene signatures
(Sun et al., 2014) revealed that genes more highly expressed in young versus aged LTHSCs were significantly enriched in NTC versus Kat6b knockdown (Figure 2.19C). On
the other hand gene more highly expressed in old vs young LT-HSCs were significantly
enriched in Kat6b knockdown vs NTC from (Sun et al., 2014) (Figure 2.19D. This might
also explain the heterogeneity among Kat6b sh1 biological replicates. as heterogeneity
due to epigenetic dysregulation in HSCs is a feature of aging (Buisman & Haan, 2019).
I then compared our dataset to previously defined gene signatures representing
HSCs (Chambers et al., 2007), the self-renewal program (Krivtsov et al., 2006),
hematopoietic progenitor cell populations (lymphoid (CLP), granulocyte-macrophage
(preGM) and erythroid-megakaryocyte (preMegE, preCFU-E, MkP)) (Sanjuan-Pla et al.,
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2013), and mature hematopoietic cell populations (M1 and M2 macrophages, monocytes,
granulocytes, erythrocytes, CD4+ naïve T cells, CD8+ naïve and activated T cells, B cells
and NK cells) (Chambers et al., 2007; Engler, Robinson, Smirnov, Hodgson, & Berger,
2012; Mantovani, Sozzani, Locati, Allavena, & Sica, 2002; Martinez, Gordon, Locati, &
Mantovani, 2006). This analysis revealed that Kat6b knockdown LT-HSCs had a
significant enrichment of an M1 macrophage signature while NTC LT-HSCs were
enriched in HSC/self-renewal, preGM, monocyte, CLP, NK and CD8+ naïve T cell
signatures (Figure 2.19E). This result is consistent with literature demonstrating
downregulation of Kat6b during macrophage polarization and M1 activation (Shukla et
al., 2018). To further interrogate mechanisms underlying the observed myeloid
differentiation bias of Kat6b knockdown LT-HSCs, unbiased GO enrichment analysis
was utilized. This analysis revealed significant upregulation of signatures associated with
defense response, immune processes and immune response in Kat6b knockdown LTHSCs (Figure 2.19F) and downregulation of signatures associated with response to
external stimulus and homeostasis (Figure 2.19G). Together, these data suggest that
decreased expression of Kat6b in LT-HSCs impairs multilineage differentiation, and
permits a transcriptional program promoting differentiation toward pro-inflammatorytype macrophages and that is associated with aging.
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2.2.5. H3K23ac levels trend towards decline in aged LT-HSCs

A

Young LT-HSCs

B

H3K23ac

DAPI

Merge

Old LT-HSCs
H3K23ac

DAPI

Merge

Figure 2.20: Alterations in H3K23ac with aging. (A) Representative
immunofluorescence images of H3K23ac and DAPI in LT-HSCs isolated from young
and aged mice. Scale bar equals 5 µm. (B) Violin plots of mean fluorescence intensity
(MFI) of H3K23ac in LT-HSCs isolated from young and aged mice. Solid lines indicate
median and dotted lines indicate quartiles. Data points include n = 25-69 individual cells
sampled from n = 4 biological replicate animals. P values calculated by unpaired t test.

As KAT6B is known to catalyze H3K23 acetylation, I hypothesized that this
modification would be decreased in LT-HSCs with aging. To test this hypothesis, I
isolated LT-HSCs from young and aged mice by FACS and immunostained with an
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antibody against H3K23ac and DAPI (Figure 2.20A). I observed a trend toward decrease
in mean fluorescence intensity of H3K23ac in LT-HSCs isolated from aged mice (P =
0.1729) (Figure 2.20B). These results suggest that H3K23ac may be modestly reduced
with age in LT-HSCs, consistent with reduction in KAT6B at the transcript and protein
levels.
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CHAPTER 3
METHODS

3.1. Experimental animals
Young C57BL/6J (2-4 months old), aged C57BL/6J (20-24 months old) and
B6.SJL-PtprcaPepcb/BoyJ (B6.CD45.1) (2-4 months old) were obtained from, and aged
within, The Jackson Laboratory. All mice used in this study were females. All
experiments were approved by The Jackson’s Laboratory Institutional Animal Care and
Use Committee (IACUC).
3.2. Plasmids
shRNA expression plasmids (in pLKO.1 or pLKO1.5) were obtained from Sigma
(St. Louis, MO) (Table 3.1).
Table 3.1. shRNA plasmids.
Target Gene Symbol

Target Gene Name

Clone Number (Sigma)

NTC

MISSION® pLKO.1-puro

SHC202 or SHC016

Non-Target shRNA Control
Plasmid DNA or TRC2
pLKO.5-puro NonMammalian shRNA Control
Plasmid DNA
Kat6b sh1

K(lysine) acetyltransferase

TRCN0000287544

6B
Kat6b sh2

K(lysine) acetyltransferase

TRCN0000039341

6B
Crebbp

CREB binding protein

TRCN0000012725

Rnf40

ring finger protein 40

TRCN0000041048
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Kmt5a

lysine methyltransferase 5A

TRCN0000241070

Atxn7l3

ataxin 7-like 3

TRCN0000251735

Tbl1x

transducin (beta)-like 1 Xlinked
ataxin 7-like 1

TRCN0000109355

Ndn

necdin

TRCN0000312951

Ezh1

enhancer of zeste 1
polycomb repressive
complex 2 subunit
lysine (K)-specific
demethylase 5B
nuclear receptor co-repressor
2
suppressor of variegation 3-9
2
PR domain containing 16

TRCN0000317140

CXXC finger 1 (PHD
domain)
dachshund family
transcription factor 1

TRCN0000257088

Atxn7l1

TRCN0000348933

Table 3.1. Continued

Kdm5b
Ncor2
Suv39h2
Prdm16
Cxxc1
Dach1

TRCN0000113491
TRCN0000095281
TRCN0000353741
TRCN0000075459

TRCN0000433533

pLKO.3G was a gift from Christophe Benoist & Diane Mathis (Addgene,
Watertown, MA; plasmid #14748). The GFP cassette from pLKO.3G was sub-cloned
into each shRNA plasmid. Colony PCR with eGFP primers (Table 3.2) was performed to
identify clones containing the GFP insert
Table 3.2. Primer sequences.
Target

Purpose

eGFP

Cloning

B2m
Kat6b
set 1

Forward Primer (5’)

GCAGTCGGCTCCCTCGTT
GACCGA
Real-time CAGTATGTTCGGCTTCCC
PCR
ATTC
Real-time AGAAGAAAAGGGGTCGT
PCR
AAACG
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Reverse Primer (5’)
CTGCACGCTCCCGTCCTCGATG
TT
TTCTGGTGCTTGTCTCACTGA
GTGGGAATGCTTTCCTCAGAA

Kat6b
set 2
Crebbp
Rnf40
Kmt5a

Real-time AGCTTCTGTTTGGGGACT
PCR
AAAG
Real-time
PCR
Real-time
PCR
Real-time
PCR

GTGTCCACTACTGCCACAATC

CCAAACGAGCCAAACTCA TTTGGACGCAGCATCTGGAA
GC
GACCCTACGGTGACGGAA CCAGTAGCGGTTGACGATGT
GT
CAGACCAAACTGCACGAC CTTGCTTCGGTCCCCATAGT
ATC

Table 3.2. Continued
Real-time
PCR
Real-time
Tbl1x
PCR
Atxn7l1 Real-time
PCR
Real-time
Ndn
PCR
Real-time
Ezh1
PCR
Real-time
Kdm5b
PCR
Real-time
Ncor2
PCR
Suv39h2 Real-time
PCR
Prdm16 Real-time
PCR
Real-time
Cxxc1
PCR
Real-time
Dach1
PCR
Knockout
PU1
Screen
Enhance Knockout
Screen
r A1

AAGGAGTGTGTTTGCCCC
AA
CACAAGTTGCACGGCTCG

AGACTTGGATCTTCGAGGGGA

CAAGCCCTAGAACAGCGT
CA
CCAGAGGAGCTAGACAG
GGT
CAACACTTCCCGCTGCAT
TC
CGAGCTGGGAAGAGTTCG
C
CCTGGTGGAAGTTCGTGG
AC
GACCGCGCCAGTTTGAAT
G
ATGGATCCCATCTACAGG
GTA
GATGATCACGGCCTACCC
TG
GGCTTTCGACCTGTTCCT
GA
AACAGATGCACGTCCTCG
AT
ATGGCCAGTCATACAAAG
GATTT

AGCAAGTTTCTGCCCTCACA

Enhance Knockout ACCGTCTAAGAGGCTTTG
Screen
GC
r B1

GCTACTAAGGCCACCGCTAG

Atxn7l3
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ACTGTGGCTTTACTCGGTGG

ACGCCTGGGGATCTTTCTTG
GGCGCTTCCGTTTTCTTGTT
ATCACAAGCGAATGGTGGCT
GCTCCTGAGACCGTTCACTC
CTAAAGGTGGGCCCTCCAAG
CATTGCATATGCCTCCGGGT
GCCGTTTGTACCTCTCCTCC
AGGAAGTTCCAGTCCAACACT
GAAGGCTGTGCTTGTGGAGT
AATGGCACAAAGAAGTCTTGA
GAA

Enhance Knockout TTGGTGCCATTTTTCACAT
Screen
GATGC
rC

AGATGTTCTTTGGCCATCACTC
T

Enhance Knockout GTCCTCCAAGAATGGGGG
Screen
TG
rD

CACCCCTCCGGTTAGGTTTC

Px458
Reverse

sgRNA
synthesis

AGCACCGACTCGGTGCCA
CT

pLENTI-CRISPR-EGFP (EGFP) was a gift from Dr. Rick Maser. PX458 plasmid
was obtained from addgene.
3.3. Lentiviral supernatant for Kat6b knockdown experiments
shRNA expression plasmids, RC-CMV-Rev1b, HDM-Hgpm2 (gag-pol), HDMtat1b, HDM-VSV-G (at a mass ratio of 10:2:2:2:1) were transfected into 5 x 106 HEK293T cells (ATCC, Manassas, VA), seeded 24 hours before transfection. CalPhos™
Mammalian Transfection Kit (Takara Bio, Mountain View, CA) was used for
transfection. Growth media was replaced 24 hours after transfection. For viral
supernatant collection, media was collected 48 hours after transfection, centrifuged at
1250 rpm for 5 min at 4oC and aliquots of supernatant were stored at -80oC.
3.4. Lentiviral supernatant for pLenti-CRISPR-EGFP transduction optimization
experiments
For 4th generation system, pLenti-CRISPR-EGFP, RC-CMV-Rev1b, HDMHgpm2 (gag-pol), HDM-tat1b, HDM-VSV-G, or for 3rd generation system PMD2.G and
pxPAX2 were transfected into 5 x 106 HEK-293T cells (ATCC, Manassas, VA), seeded
24 hours before transfection. CalPhos™ Mammalian Transfection Kit (Takara Bio,
Mountain View, CA) was used for transfection. Growth media was replaced 24 hours
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after transfection. For viral supernatant collection, media was collected 48 hours after
transfection, centrifuged at 1250 rpm for 5 min at 4oCand used either fresh or aliquots of
supernatant were stored at -80oC.
3.5. Titering of viral supernatant
To titer lentiviral supernatant, 2 x 105 NIH/3T3 cells (ATCC) were seeded in a 6well plate 24 hours before supernatant was thawed and added at 1:2, 1:10, 1:50, 1: 250
and 1:1250 diluted in DMEM+10%FBS with 5 ug/ml polybrene. Plates were spun at
2500 rpm for 60 min at room temperature followed by incubation at 37oC and 5% CO2
for 48 hours with media change after 24 hours. After this 48h culture period, cells were
harvested and run on a LSRII (BD Biosciences, San Jose, CA) to assess frequency of
GFP+ cells. These frequencies were used to calculate the titer of each preparation of
lentiviral supernatant. In addition, RNA was isolated from transduced NIH/3T3 cells to
assess shRNA knockdown efficiency by real-time PCR.
3.6. Primary cell isolation
LT-HSCs and MPP4 cells were isolated as described previously (Young et al.,
2016b). Femurs, tibiae, iliac crests from each mouse were pooled, crushed and filtered to
prepare single-cell suspensions of bone marrow (BM). Ficoll-Paque (GE Healthcare,
Chicago, IL) density centrifugation was used to isolate BM mononuclear cells (MNCs).
These cells were stained with fluorochrome-conjugated antibodies from BioLegend (San
Diego, CA), eBiosciences (ThermoFisher Scientific, Waltham, MA), BD Biosciences
(San Jose, CA): c-Kit (clone 2B8), CD48 (clone HM48-1), CD150 (clone TC1512F12.2), Sca-1 (clone D7), FLT3 (clone A2F10), mature lineage (Lin) marker mix
(B220 (clone RA3-6B2), CD11b (clone M1/70), CD4 (clone RM4-5), CD8a (clone 5382

67), Ter-119 (clone TER-119), Gr-1 (clone RB6-8C5), CD5 (clone 53-7.3)) and viability
stain propidium iodide (PI). Cells were sorted on a FACSAria (BD Biosciences) with
these surface marker profiles: LT-HSC (Lin- Sca+ c-Kit+ CD150+ CD48-), MPP4 cells
(Lin- Sca+ c-Kit+ Flt3+), LSK cells (Lin- Sca+ c-Kit+) and LK cells (Lin- c-Kit+).
3.7. Transduction of LT-HSCs, MPP4 Cells
LT-HSCs were resuspended in SFEMII (StemCell Technologies, Vancouver,
Canada) supplemented with growth factors described previously (Holmfeldt et al., 2016);
Stem cell factor (SCF; 10 ng/ml), thrombopoietin (TPO; 20 ng/ml), insulin-like growth
factor 2 (IGF2; 20 ng/ml) and fibroblast growth factor (FGF; 10 ng/ml) (BioLegend or
StemCell Technologies) along with 5ug/ml polybrene (Sigma) and viral supernatant.
Lentiviral supernatant was added at concentration of 1000 MOI in a total volume of 200
ul in a 96-well U-bottom plate. The plate was spun at 2500 rpm for 60 min at room
temperature. After this, cells were cultured at 37oC and 5% CO2 for 36 hours. Transduced
cells (viable GFP+) were sorted on a FACSAria (BD Biosciences). MPP4 cells were
handled as above in IMDM (ThermoFisher Scientific) supplemented with 10% FBS
(VWR, Radnor, PA), interleukin-3 (IL-3, 10 ng/ml ), interleukin-6 (IL-6, 10 ug/ml),
interleukin-7 (IL-7, 20 ng/ul), SCF (100 ng/ml), leukemia inhibitory factor (LIF, 20
ng/ml) (Peprotech, Rocky Hill, NJ) and polybrene (5 ug/ml) (Sigma).
3.8. Generation of concentrated virus by ultracentrifugation
shRNA expression plasmids, RC-CMV-Rev1b, HDM-Hgpm2 (gag-pol), HDMtat1b, HDM-VSV-G (at a mass ratio of 10:2:2:2:1) were transfected into 5 x 106 HEK293T cells (ATCC, Manassas, VA), seeded 24 hours before transfection. CalPhos™
Mammalian Transfection Kit (Takara Bio, Mountain View, CA) was used for
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transfection. Growth media was replaced 24 hours after transfection. For viral
supernatant collection, media was collected 48 hours after transfection, centrifuged at
1250 rpm for 5 min at 4oC and filtered through a 0.45uM filter. Filtrate was centrifuged at
25000 rpm for 90 mins. Viral pellet was incubated at 4C overnight, followed by
resuspension. Aliquots of supernatant were stored at -80oC.
3.9. Electroporation of Cas9-sgRNA RNPs in HSPCs:
Electroporation protocol was adapted from (Gundry et al., 2016).LK cells were
cultured for three in presence of 10 ng/ml SCF 100 ng/ml TPO in SFEMII media for
three hours. Cells were resuspended in 10 ul of Buffer T (Neon Transfection Kit).
1 ug of Cas9 protein (PNABio) was incubated with 1 ug of in vitro transcribed sgRNA
(0.5 ug of each sgRNA was used which flanked the target knockout region) in a total
volume of 2 ul for 15 mins at RT. RNP complexes were combined with resuspended cells
and electroporated at 1700 V, 20 ms (Neon Transfection System) followed by cell count
and plating into OP9 co-culture assay.
Screen for knockout was performed by isolation of genomic DNA of cells with
DNeasy Blood and Tissue Kit (Qiagen) and performing PCR by using primers listed in
Table 3.2.
3.10. In vitro synthesis of sgRNAs
Oligos containing T7 promoter and variable region of sgRNAs against candidate
loci were ordered from Integrated DNA Technologies (Table 3.3).
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Table 3.3. Oligos for CRISPR/Cas9 knockout.
Target

Purpose

PU1

Cas9
GAAATTAATACGACTCAC
Knockout TATAAGTCCATAAGGGAT
AGCCCAGTTTTAGAGCTA
GAAATAGC
Cas9
GAAATTAATACGACTCAC
Knockout TATAGGGCAAGGGTGTAA
AGAAGTGTTTTAGAGCTA
GAAATAGC
Cas9
GAAATTAATACGACTCAC
Knockout TATAAGAAGAGAGTGCAC
TCACAGGTTTTAGAGCTA
GAAATAGC
Cas9
GAAATTAATACGACTCAC
Knockout TATAAGTAGCTATTTGGA
ACCTGAGTTTTAGAGCTA
GAAATAGC
Cas9
GAAATTAATACGACTCAC
Knockout TATAGAACCTTGGGAATA
CAACACGTTTTAGAGCTA
GAAATAGC

Enhance
r A1
Enhance
r B1
Enhance
rC
Enhance
rD

sgRNA 1

sgRNA2
GAAATTAATACGACTCACTATA
AGACTCCCAAGGAAGCACCGG
TTTTAGAGCTAGAAATAGC
GAAATTAATACGACTCACTATA
GGGCAAGGGTGTAAAGAAGTG
TTTTAGAGCTAGAAATAGC
GAAATTAATACGACTCACTATA
AGATTGGCAAGGGCTCACAGGT
TTTAGAGCTAGAAATAGC
GAAATTAATACGACTCACTATA
GGTTGATGATCAGTATGTGAGT
TTTAGAGCTAGAAATAGC
GAAATTAATACGACTCACTATA
GGGAGTACCTGGTGTTCCAAGT
TTTAGAGCTAGAAATAGC

These oligos were used as primers to PCR amplify scaffold region of sgRNA
from PX458 plasmid followed by purification of PCR products by QIAquick PCR
Purification Kit (Qiagen). In vitro RNA transcription of these PCR products was
performed by HiScribe T7 High Yield RNA Synthesis Kit (NEB) followed by
purification and concentration by RNA Clean & Concentrator-25 (Zymo Research).
3.11. OP9 co-culture for differentiation to B-lymphoid cells
OP9 co-culture protocol was adapted from (Pietras et al., 2015a). OP9 cells were
cultured with MEM-α media 89%, FBS 10%, Pen/Strep 1%. On Day -1 OP-9 cells were
seeded in 96-well or 24-well plate. LSKs or LKs were added to pre-seeded OP9 cells in
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200 ul of B-cell media (optiMEM 93.9% , FBS 5%, Pen/strep 1%, 1% of 55mM Bmercaptoethanol 0.1%, SCF 10 ng/ml, Flt3L 10 ng/ml, IL-7 5 ng/ml). On Day 2, half
media was replaced with fresh media (optiMEM 93.9% , FBS 5%, Pen/strep 1%, 55mM
B-mercaptoethanol 0.1%, SCF 10 ng/ml, IL-7 5 ng/ml). On Day 5, half media was
replaced with fresh media (optiMEM 93.9% , FBS 5%, Pen/strep 1%, 55mM Bmercaptoethanol 0.1%, IL-7 5 ng/ml). After this media was changed every 2-3 days same
as done on Day 5. When the OP9 layer started to detach from the periphery, 5000 OP9
cells were seeded in 1 well of a 24 well plate. Cells were harvested by trypsinization.
Resuspended in 200 ul of B-cell media (same composition as Day 5 of assay) along with
old media from 96-well plate.
3.12. Transduction optimization experiments for pLenti-CRISPR-EGFP
For Figure 2.8 1 x 106 whole bone marrow cells were resuspended in 1.8 ml of
respective viral supernatant supplemented with 5% FBS, SCF (100 ng/ml) and Polybrene
(13.5 ug/ml). Cells were spun at 2500 rpm for 1 hour. After overnight culture, cells were
resuspended in SFEMII with SCF (100 ng/ml).
For Figure 2.9 approximately 9000 LSKs were resuspended in SFEMII media
supplemented with SCF (100 ng/ml), Polybrene (5 ug/ml) with 8% by volume pLENTICRISPR-EGFP viral supernatant. Cells were spun at 1800 rpm for 30 min. After
overnight culture, cells were transduced with similar conditions as Day 1.
For Figure 2.10 approximately 4000 LSK cells were resuspended in SFEMII
media supplemented with SCF (100 ng/ul), Polybrene (8 ug/ml) and 10%, 50% or 70%
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pLENTI-CRISPR-EGFP viral supernatant. Cells were spun at 2500 rpm for 60 mins.
After overnight culture, transduction was repeated as performed on Day 1.
For Figure 2.11 approximately 2000 LSKs were resuspended in IMDM medium
with 0.5%, 10% or 50% of concentrated viral supernatant, SCF (100 ng/ul), Polybrene
(5ug/ml) made up to 200 ul total volume with IMDM 10% FBS. Cells were spun at 2500
rpm for 60 mins. After overnight culture cells were resuspended in IMDM 10% FBS.
3.13. Colony forming unit (CFU) Assays
For B-lymphoid CFU assays, 100 GFP+ cells from transduced MPP4 cells were
plated in Methocult M3630 (StemCell Technologies) supplemented with FMS-like
tyrosine kinase like 3 ligand (FLT3L, 25 ng/ml) and SCF (50 ng/ml) (Peprotech). For
myeloid CFU assays, 100 GFP+ cells from transduced MPP4 cells or 200 GFP+ cells from
transduced LT-HSCs were plated in Methocult GF M3434 (StemCell Technologies) and
cultured at 37oC and 5% CO2. Scoring of colonies was done between days 7 and 10 using
a Nikon Eclipse TS100 inverted microscope. CFU cloning efficiency was calculated as
the sum of the myeloid and B-lymphoid colonies divided by the sum of the myeloid and
B-lymphoid colonies in the NTC group. For analysis of replating potential, colonies were
harvested and total viable counts were obtained, followed by plating of 1-3 x 104 cells in
Methocult GF M3434. Remaining cells were resuspended in RLT buffer (Qiagen, Hilden,
Germany). RNA was isolated by RNeasy Micro or RNeasy Mini kits (Qiagen) followed
by cDNA synthesis using the SuperScript™ III First-Strand Synthesis SuperMix
(ThermoFisher Scientific).
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3.14. Real-time PCR
Real-time PCR was performed using RT2 SYBR Green ROX qPCR Mastermix
(Qiagen) using the Viaa7 or QuantStudio 7 Flex (Applied Biosystems, Foster City, CA).
Refer to Supplemental Table 5 for primer sequences used.
3.15. Immunofluorescence staining of LT-HSCs
Staining was performed as previously described (Florian et al., 2012). Sorted LTHSCs were seeded on retronectin-coated glass coverslips in SFEMII supplemented with
SCF (10 ng/ml), TPO (20 ng/ul), IGF2 (20 ng/ul), FGF (10 ng/ul) (BioLegend or
StemCell Technologies) for at least 2 hours. Cells were fixed in 4% PFA (ThermoFisher
Scientific). Cells were washed with PBS, permeabilized with 0.2% Triton X-100
(ThermoFisher Scientific) in PBS for 20 mins and blocked with 10% goat serum
(ThermoFisher Scientific) for 20 mins. Cells were stained by either α-KAT6B (NBP192036; Novus Biologicals, Centennial, CO) or α-H3K23ac (ab61234; Abcam,
Cambridge, UK) for one hour at room temperature. For secondary antibody, cells were
stained with α-Rabbit conjugated with Alexa-568 (A-11036; ThermoFisher Scientific) for
one hour. Coverslips were mounted on slides with Gold Antifade with DAPI
(ThermoFisher Scientific). Imaging was performed with Leica SP8 confocal microscope.
Z-stack images were summed and quantification of individual fluorescence intensities
was performed by Fiji software (Schindelin et al., 2012). Cells were detected by Fiji in
range of 150-250 pixel units. Scale bars in images represent 5 um.
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3.16. In Vivo transplantation
200-350 transduced GFP+ cells were combined with 5 x 105 bone marrow
mononuclear cells (MNCs) from B6.CD45.1 mice and retro-orbitally injected into
recipient B6.CD45.1 mice after 1000 rads gamma irradiation (split dose). Peripheral
blood from recipient mice was analyzed by flow cytometry every 4 weeks after
transplantation. Blood was collected by retro-orbital bleeding and stained with a
combination of fluorochrome-conjugated antibodies from BioLegend or BD Biosciences
with or without red blood lysis: CD45.1 (clone A201.7 or clone A20), CD45.2 (clone
104), B220 (clone RA3-6B2), CD3e (clone 145-2C11), CD11b (clone M1/70), Ly6g
(clone 1A8), Ly6c (clone HK1.4), Ter-119 (clone TER-119), GR1 (clone RB6-8C5),
CD4 (clone GK1.5), CD8a (clone 53-6.72) and CD41 (clone MWReg30). Stained cells
were run on a FACSymphony A5 (BD Biosciences) and data was analyzed using FlowJo
software (FlowJo, LLC, Ashland, OR).
3.17. RNA-Seq
Transduced GFP+ LT-HSCs from 3 independent biological replicates were sorted
directly into 350 ul of RLT buffer (Qiagen). Total RNA was isolated from cells using the
RNeasy Micro kit (Qiagen), according to manufacturers’ protocols, including the optional
DNase digest step. Sample concentration and quality were assessed using the Nanodrop
2000 spectrophotometer (ThermoFisher Scientific) and the RNA 6000 Pico LabChip
assay (Agilent Technologies, Santa Clara, CA). Libraries were prepared by the Genome
Technologies core facility at The Jackson Laboratory using the Ovation RNA-seq System
V2 (NuGEN Technologies, Redwood City, CA) and Hyper Prep Kit (Kapa Biosystems,
Wilmington, MA). Briefly, the protocol entails first and second strand cDNA synthesis
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and cDNA amplification utilizing NuGEN’s Ribo-SPIA technology, cDNA
fragmentation, ligation of Illumina-specific adapters containing a unique barcode
sequence for each library, and PCR amplification. Libraries were checked for quality and
concentration using the D5000 ScreenTape assay (Agilent Technologies) and quantitative
PCR (Kapa Biosystems), according to the manufacturers’ instructions. Libraries were
pooled and sequenced 75 bp single-end on the NextSeq 500 (Illumina, San Diego, CA)
using NextSeq High Output Kit v2.5 reagents. Raw and processed data was deposited in
the Gene Expression Omnibus (GEO accession GSE133304).
3.18. RNA-seq analysis
Trimmed alignment files (with trimmed base quality value < 30, and 70% of read
bases surpassing that threshold) were processed using the RSEM (v1.2.12; RNA-Seq by
Expectation-Maximization) software (B. Li & Dewey, 2011) and the Mus Musculus
reference GRCm38. Alignment was completed using Bowtie 2 (v2.2.0) (Langmead &
Salzberg, 2012) and processed using SAMtools (v0.1.18) (H. Li et al., 2009). Fragment
length mean was set to 280 and standard deviation to 50. Expected read counts per gene
produced by RSEM were rounded to integer values, filtered to include only genes that
have at least two samples within a sample group having a cpm > 1.0, and were passed to
edgeR (v3.5.3) (Robinson, Mccarthy, & Smyth, 2010) for differential expression
analysis. The negative binomial conditional common likelihood was maximized to
estimate a common dispersion value across all genes. Exact tests were used to elucidate
statistical differences between the two sample groups of negative-binomially distributed
counts producing p-values per test. The Benjamini and Hochberg’s algorithm (p-value
adjustment) was used to control the false discovery rate (FDR). Features with an FDR90

adjusted p-value < 0.05 were declared significantly differentially expressed. Gene set
enrichment analysis (GSEA) (Daly et al., 2003; Subramanian et al., 2005) was performed
using previously published aged LT-HSC RNA-seq data (Sun et al., 2014) and previously
defined gene signatures representing HSCs (Chambers et al., 2007), the self-renewal
program (Krivtsov et al., 2006), hematopoietic progenitor cell populations (lymphoid
(CLP), granulocyte-macrophage (preGM) and erythroid-megakaryocyte (preMegE,
preCFU-E, MkP)) (Sanjuan-Pla et al., 2013), and mature hematopoietic cell populations
(M1 and M2 macrophages, monocytes, granulocytes, erythrocytes, CD4+ naïve T cells,
CD8+ naïve and activated T cells, B cells and NK cells) (Chambers et al., 2007; Engler et
al., 2012; Mantovani et al., 2002; Martinez et al., 2006) (Supplemental Table 3).
3.19. Statistical analysis
Sample groups were compared using an unpaired t test, Mann-Whitney test, oneway ANOVA and Holm-Sidak’s multiple comparisons test, or two-way ANOVA and
Dunnett’s multiple comparisons test as indicated in figure legends.Prism software
(GraphPad Software, San Diego, CA) was utilized for statistical calculations and
graphing.
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CHAPTER 4
DISCUSSION
4.1. OP9 co-culture of HSPCs is a qualitative assay
I have reproduced the finding that the OP9 co-culture of HSPCs is successful at the
production of CD19+ B-lymphoid cells as has been earlier reported (Pietras et al., 2015b).
However, I observed that this assay shows considerable heterogeneity with respect to
efficiency of differentiation of HSPCs to mature cells. I did not find any correlation
between the number of HSPCs which were input in the start of assay and the number of
CD45+ cells produced at the end. This was the first indication that this assay was suitable
for qualitative measure of B-lymphoid differentiation potential rather than quantitative
assessment. However, I attributed this heterogeneity in the performance of this assay to
the culture conditions. After 7-10 days of culture the OP9 layer started to detach from the
surface of a 96-well plate, at which time OP9 and HSPCs were harvested by
trypsinization and centrifugation and were transferred to a well 24 well plate containing
pre-seeded OP9 cells for rest of the assay. I hypothesized that this step was the source of
variability of this assay and so I tested this hypothesis by performing the assay starting
from 96-well and 24-well and continuing the culture for 12 days without re-plating. I
observed that these conditions produced CD19+ cells with lower efficiency as compared
to the 23-day long culture with re-plating and there was still heterogeneity among
technical replicates. I also attempted to culture HSPCs in transwells which allowed
transfer the of HSPCs to a new well without trypsinization steps, however, the percentage
of CD19+ cells was considerably lower as compared to cells cultured with initial
conditions and variability in output persisted. Although this experiment did not solve the
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problem of variability in output, it did provide evidence that HSPCs differentiation into
CD19+ cells is dependent on contact with OP9 cells. It can also be inferred from these
experiments that the variability in OP9 co-culture of HSPCs could stem from the
heterogeneity in OP9 cells themselves which would result in heterogeneity in the
performance of the assay. Although another cell line, S17, has been used for in vitro
differentiation to lymphoid cells, OP9 cells were found to be 30% more efficient (Viera
& Cumano, 2004). Therefore, among current methods, OP9 coculture of HSPCs cells is
the most appropriate method for assessment of in vitro B-lymphoid differentiation
potential. That is why this assay is widely used in the field (Adolfsson et al., 2005;
Akashi K et al., 2000; Arinobu et al., 2007; Pietras et al., 2015a). My findings provide
evidence that OP9 co-culture assay is more suitable for qualitative assessment of Blymphoid differentiation potential, rather than quantitative analyses. Therefore, these
findings provide important considerations for the application of the OP9 co-culture assay.
It is also possible that the heterogeneity that I observed in my results could stem from the
use of a heterogeneous population of HSPCs. The use of HPSCs for these experiments
was important due to the biological question that I was asking regarding their
differentiation. Therefore, I propose that future studies should involve studying the effect
of using more purified hematopoietic progenitor populations like CLPs in the OP9 coculture. I also propose that further studies should involve the generation of a more
homogenous OP9 cell line and determining the exact cell receptors or molecules secreted
by these cells which promote B-lymphoid differentiation, which will allow more
controlled in vitro differentiation culture systems.
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4.2. The OP9 assay is not suitable for enhancer loss of function studies
Enhancers often act in a combinatorial manner in which activities of multiple enhancers
contribute to the expression of a single target gene (Maekawa, Imamoto, Merlino, Pastan,
& Ishii, 1989; Osterwalder et al., 2018). In vivo knockout of experimentally validated
limb specific enhancers did not produce any limb morphology phenotypes, whereas
deletion of two enhancers did produce in a discernable phenotype showing the presence
of redundancy in enhancer function as well (Osterwalder et al., 2018). In context of the
hematopoietic system, synergy between two enhancers, HS1 and HS2, of Gata1, a gene
important for erythroid lineage, has also been established (Testa et al., 2004). Therefore,
in the context of the loss of function studies involving the deletion of a single enhancer
that I attempted, the expected phenotype is likely to be subtle. And, these subtle
phenotypes were probably masked by the heterogeneity and qualitative nature the of OP9
assay. This is a possible explanation that why I did not observe a significant reduction in
B-lymphoid differentiation of HSPCs after knockout of Pu.1. These technical challenges
could be overcome by performing an in vivo screen for these putative lymphoid specific
enhancers. Such a screen would involve targeting enhancers by a library of genome-wide
sgRNAs in HSPCs isolated from Cas9 expressing mice, followed by transplantation in
conditioned recipients. Prevalence of sgRNA tags in donor-derived B-cells would a
measure of relative importance of each enhancer for differentiation to B-cells.
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4.3. Kat6b is a novel therapeutic target for ameliorating aging-associated decline in
HSCs
By employing a shRNA-mediated screen of epigenetic regulators, we have
discovered a novel role for Kat6b in the context of LT-HSC differentiation with
relevance to aging. I have found that KAT6B decreases in aged HSCs at the transcript
and protein levels. The knockdown of Kat6b in young LT-HSCs resulted in an increase in
the proportion of myeloid cells and a decrease in the proportion of erythroid cells in vitro
and in vivo, demonstrating myeloid lineage-biased differentiation. I did not observe any
BFU-E/CFU-E colonies in vitro, perhaps due to the effect of 2-day culture conditions on
the differentiation potential of LT-HSCs before setting up CFU assays. Transcriptome
data revealed that knockdown of Kat6b resulted in loss of HSC-associated expression
signatures as well as multilineage priming, while gaining an M1 pro-inflammatory
macrophage expression signature. HSPCs have been known to express myeloid genes
(Iwasaki and Akashi, 2007) and my in vitro and in vivo data show an increase in
differentiation towards myeloid cells. Thus, knockdown of Kat6b might be causing
expression of myeloid associated genes which might have led to an enrichment in gene
signatures associated with M1 macrophages. In addition, it has been reported that Kat6b
expression is reduced in macrophages under LPS stimulation which results in M1
activation (Shukla et al., 2018). LPS results in immune activation and we have shown
that knockdown of Kat6b also results in GO terms associated with immune response
(Figure 5E). So, it is possible that immune response mediated by reduction in Kat6b is
resulting in the activation of M1 gene expression profiles. Together, my results support
that Kat6b functions as a regulator of HSC self-renewal and multilineage differentiation
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and decrease in Kat6b promotes myeloid lineage-biased HSC differentiation, similar to
results observed in aging.
This work builds upon literature demonstrating the importance of the MYST
family of acetyltransferases for LT-HSC function. KAT6A, a paralogue of KAT6B with
structural similarity (Simpson et al., 2012), also has important functions in the regulation
of HSPCs (Sheikh et al., 2016). My results support overlapping but non-redundant roles
for KAT6A and KAT6B in hematopoiesis. In vitro, Kat6a-deficient bone marrow has
reduced total number of colonies in the CFU assay including reduction in all colony
subtypes (Sheikh et al., 2016), whereas I observed that Kat6b knockdown results in no
change in total colony numbers and a proportional increase in myeloid-only colonies. In
vivo, conditional knockout of Kat6a resulted in impaired competitive repopulation
capacity and increased ratio of myeloid to lymphoid differentiation (Sheikh et al., 2016),
whereas Kat6b knockdown resulted in no significant change in repopulation capacity or
B cell frequency, increased frequency of myeloid cells and decreased frequency of RBCs.
Thus, I propose that KAT6A and KAT6B have overlapping but distinct roles in proper
multilineage differentiation from LT-HSCs.
In the context of my experiments, LT-HSCs were cultured under ex vivo
conditions which have been reported to promote HSC self-renewal (Holmfeldt et al.,
2016). However, this requirement for ex vivo culture for lentiviral transduction is also a
caveat in the interpretation of our results. It is possible that some or all of the LT-HSCs
seeded into ex vivo culture differentiate to progenitors during the 36h transduction culture
period. Thus, the Kat6b knockdown phenotype I observe may be manifest in either HSCs
or their myeloid progenitor progeny. In addition, ex vivo culture conditions of LT-HSCs
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before CFU assay might also explain lack of observation of erythroid colonies like BFUE and CFU-E from my experiments. Therefore, to overcome these caveats and further
test the hypothesis that Kat6b is important for regulation of HSC differentiation to
myeloid and erythroid lineages, it would be important to perform loss of function studies
of Kat6b in adult bone marrow by using an inducible system. These experiments would
involve engineering a Kat6b inducible knockout mouse consisting of floxed Kat6b. The
knockout would be induced specifically in bone marrow at adult (2-4 months) stage.
Uninduced floxed mice will be used as negative controls. After induction of knockout of
Kat6b, HSCs will be isolated from experimental and control mice and transplanted in
conditioned recipients. Peripheral blood and bone marrow composition of these mice will
be measured at 6 months post transplantation to test the hypothesis that knockout of
Kat6b results in increase in differentiation to myeloid and reduction in differentiation to
erythroid cell types as I observed in in vivo experiments involving transplantation of
HSCs after Kat6b knockdown by lentiviral transduction. To assess that if Kat6b knockout
affects stem cell self-renewal, HSCs from recipient mice will be isolated and transplanted
into secondary recipients.
Both NTC and Kat6b sh1 transplanted mice had low donor-derived reconstitution
ability and also declined across 4-month time period post-transplant. This observation can
be attributed to culture conditions during transduction not being sufficient to keep the
HSCs in stem cell state completely. Another possible reason is that effect of lentiviral
transduction on reconstitution ability of stem cells. It has been reported that transduction
followed by transplantation usually results in low reconstitution (Barrette et al., 2000;
Hosokawa et al., 2010; Kinkel et al., 2015; Kumar et al., 2019; Mazumdar et al., 2015)
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and also declines with time (Passegué et al., 2004). Higher engraftment by transduction
and transplantation methods are observed in proliferation inducing phenotypes (Hope et
al., 2004). Since I did not observe any evidence that Kat6b knockdown is inducing any
malignant transformation of cells, that’s why low reconstitution of transplanted cells can
be explained by their transduction.
As a proof of principle that aged HSCs can be rejuvenated by therapeutic interventions
that target epigenetic regulatory processes, it has been shown that inhibition of CDC42 by
CASIN restored the polarity of H4K16ac, Cdc42 and Tubulin in aged HSCs (Florian et
al., 2012). These CASIN-treated aged HSCs had re-balanced B-lymphoid and myeloid
differentiation potential in vivo and HSC frequency resembling young animals (Florian et
al., 2012), although a subsequent study has shown that simply increasing the levels of
H4K16ac using a pan-HDAC inhibitor is not sufficient to restore HSC function
(Grigoryan et al., 2018). In addition, reprogramming of aged HSCs to induced pluripotent
stem cells (iPSCs) has been shown to rejuvenate in vivo engraftment and T cell
differentiation potential (Wahlestedt et al., 2013). My work suggests that therapeutically
increasing levels of KAT6B in aged HSCs may also rejuvenate aspects of altered
functionality, particularly with respect to lineage-balanced differentiation. A recent report
by Adelman et al. demonstrated a reduction in active enhancer-associated chromatin
modifications at a KAT6B-proximal enhancer region in aged versus young human HSCs
(Adelman et al., 2019), suggesting that therapeutic approaches to increase enhancer
activity may be a viable strategy to boost Kat6b expression in aged HSCs. Further studies
will be required to test whether restoring expression of Kat6b in aged HSCs to levels
observed in young HSCs is sufficient to restore balanced lineage differentiation.
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CHAPTER 5
CONCLUSIONS
Hematopoiesis is a well-coordinated continuous process of differentiation from HSCs to
mature blood and immune cells. Investigations of molecular mechanisms of this process
have not only provided us with knowledge regarding the origin of blood disorders and
malignancies but have also been instrumental in elucidating basic molecular and cellular
mechanisms underlying stem cell function and differentiation. These studies have relied
on a variety of in vitro and in vivo assays, that is why robustness and correct applications
of a particular assay are key to interpreting the results obtained from that assay. In my
thesis work, I have investigated the robustness of OP9 co-culture assay for the
differentiation of HSPCs to B-lymphoid cells. My experiments have reproduced findings
from literature which support that this assay is successful in differentiation of HSPCs to
B-lymphoid cells. However, I have contributed to the body of literature in this field by
showing that this assay provides a qualitative measure of differentiation potential and
therefore is not suitable for studies involving quantitative assessment of differentiation
potential. This provides novel insights into the application of this assay for assessment of
B-lymphoid differentiation capacity. I have also demonstrated that one (enhancer B1) of
out of 4 putative lymphoid enhancers showed a subtle defect in differentiation towards Blymphoid cells after knockout as compared to the negative control, whereas rest of
investigated enhancers did not show any difference. There can be a couple of
interpretations from these results. Since enhancer B1 belonged to the category of predisposed enhancers, therefore, it can be inferred that pre-disposed enhancers are more
important for commitment and differentiation to lymphoid lineage as compared to de
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novo established enhancers. Secondly, it is possible that these enhancers are acting in a
redundant manner which might explain subtle or no phenotypes after knockout of single
enhancers.
In addition, I have also studied the cellular and molecular mechanism underlying
differentiation of HSCs to myeloid cells with links to aging-associated phenotypes. Some
of the key cellular phenotypes hematopoietic aging are a reduction in differentiation to
erythroid and increase in the production of myeloid cell types. I have demonstrated that
loss of function of Kat6b by knockdown approaches results in impaired differentiation to
erythroid cell types and enhanced differentiation to myeloid cell types in vitro and in vivo
from HSCs (Figure 5.1).

Figure 5.1. Model of link between Kat6b and aging-associated hematopoietic decline.
By performing transcriptomic analysis after Kat6b knockdown I have demonstrated that
reduction in Kat6b expression results in gene expression profiles that partially
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recapitulate aging-associated gene signatures. Furthermore, I have shown that transcript
and protein levels of KAT6B decline with age in murine HSCs. This provides Kat6b as a
novel therapeutic target whose over-expression in aged HSCs could potentially
rejuvenate aging-associated decline in the hematopoietic system.
Therefore, I have demonstrated in my thesis that gene regulatory and epigenetic
elements are important for the differentiation of HSPCs to mature cells. I have also
shown that epigenetic regulators like Kat6b are linked with aging-associated decline in
the hematopoietic systems and alterations in levels of such epigenetic regulators can be
one of the contributing factors which drive aging-associated hematopoietic decline.
Future studies in these areas should involve investigation of combinatorial approaches
involving targeting gene regulatory elements and associated epigenetic regulators to
boost hematopoietic function with age. These studies will consist of in vivo genome-wide
screens to identify cis-regulatory elements which are important for differentiation to
mature lineages, and tracking changes in the activation status of these cis-regulatory
elements. These will be followed by the recruitment of dCas9 fused epigenetic effectors
to these cis regulatory elements in old HSCs to correct the changes that have accrued due
to aging. The long-term goal of such studies would be to obtain comprehensive
knowledge about molecular and cellular mechanisms that go awry with aging, so that
therapeutic strategies to treat aging-associated diseases can be developed.
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